<SEC-DOCUMENT>0001193805-22-001637.txt : 20230214
<SEC-HEADER>0001193805-22-001637.hdr.sgml : 20230214

<ACCEPTANCE-DATETIME>20221202143618

<PRIVATE-TO-PUBLIC>

ACCESSION NUMBER:		0001193805-22-001637

CONFORMED SUBMISSION TYPE:	PRRN14A

PUBLIC DOCUMENT COUNT:		7

FILED AS OF DATE:		20221202

DATE AS OF CHANGE:		20221202


SUBJECT COMPANY:	


	COMPANY DATA:	

		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.

		CENTRAL INDEX KEY:			0001053691

		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]

		IRS NUMBER:				300645032

		STATE OF INCORPORATION:			DE

		FISCAL YEAR END:			1231



	FILING VALUES:

		FORM TYPE:		PRRN14A

		SEC ACT:		1934 Act

		SEC FILE NUMBER:	001-37942

		FILM NUMBER:		221441504



	BUSINESS ADDRESS:	

		STREET 1:		300 EAST MAIN STREET

		STREET 2:		SUITE 201

		CITY:			CHARLOTTESVILLE

		STATE:			VA

		ZIP:			22902

		BUSINESS PHONE:		(434) 220-0718



	MAIL ADDRESS:	

		STREET 1:		300 EAST MAIN STREET

		STREET 2:		SUITE 201

		CITY:			CHARLOTTESVILLE

		STATE:			VA

		ZIP:			22902



	FORMER COMPANY:	

		FORMER CONFORMED NAME:	RestorGenex Corp

		DATE OF NAME CHANGE:	20140307



	FORMER COMPANY:	

		FORMER CONFORMED NAME:	Stratus Media Group, Inc

		DATE OF NAME CHANGE:	20080722



	FORMER COMPANY:	

		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.

		DATE OF NAME CHANGE:	20080228




FILED BY:		


	COMPANY DATA:	

		COMPANY CONFORMED NAME:			LifeSci Management Co LLC

		CENTRAL INDEX KEY:			0001955680

		IRS NUMBER:				000000000



	FILING VALUES:

		FORM TYPE:		PRRN14A



	BUSINESS ADDRESS:	

		STREET 1:		250 WEST 55TH STREET

		CITY:			NEW YORK

		STATE:			NY

		ZIP:			10019

		BUSINESS PHONE:		212-915-2565



	MAIL ADDRESS:	

		STREET 1:		250 WEST 55TH STREET

		CITY:			NEW YORK

		STATE:			NY

		ZIP:			10019



</SEC-HEADER>

<DOCUMENT>
<TYPE>PRRN14A
<SEQUENCE>1
<FILENAME>prrn14a13616001_12012022.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A<BR>
</B>(Rule 14a-101)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INFORMATION REQUIRED IN PROXY STATEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE 14A INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> (Amendment No. 1) </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filed by
the Registrant </FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filed by a
Party other than the Registrant </FONT>&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9746;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary
Proxy Statement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitive
Proxy Statement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitive
Additional Materials</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting
Material Under Rule 14a-12</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">DIFFUSION PHARMACEUTICALS INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Name of Registrant as Specified in Its Charter)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">LIFESCI
SPECIAL OPPORTUNITIES MASTER FUND LTD.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">LIFESCI
SPECIAL OPPORTUNITIES OFFSHORE FUND, LTD.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">LIFESCI
SPECIAL OPPORTUNITIES PARTNERS GP, LLC</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">LIFESCI
MANAGEMENT COMPANY, LLC</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">PIRATE
COVE CAPITAL LTD.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">DAVID
DOBKIN</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">JILL DAVIDSON</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TENZIN KHANGSAR</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">JEFFREY KIMBELL</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">JESSICA M. LOCKETT</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">JEFFREY MAX</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">JOHN S. ZIEGLER</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Name of Persons(s) Filing Proxy Statement, if Other Than the Registrant)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9746;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">No
fee required</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Fee
paid previously with preliminary materials</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Fee
computed on table in exhibit required by Item 25(b) per Exchange Act Rules &#9;14a-6(i)(1) and 0-11</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>PRELIMINARY COPY SUBJECT TO COMPLETION<BR>
DATED <FONT STYLE="text-transform: uppercase">deceMBER 2</FONT>, 2022 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>LifeSci
Special Opportunities Master Fund Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">______________, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Fellow Diffusion Stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci Special Opportunities
Master Fund Ltd., a Cayman Island exempted company (together with its affiliates &ldquo;LifeSci&rdquo;, &ldquo;us&rdquo; or &ldquo;we&rdquo;),
and the other participants in this solicitation are significant stockholders of Diffusion Pharmaceuticals Inc., a Delaware company (&ldquo;Diffusion&rdquo;
or the &ldquo;Company&rdquo;), who beneficially own, in the aggregate, 96,976 shares of common stock, $0.001 par value per share (the
 &ldquo;Common Stock&rdquo;), of the Company. We are seeking your support at the Company&rsquo;s upcoming 2022 annual meeting of stockholders
(the &ldquo;Annual Meeting&rdquo;) to elect LifeSci&rsquo;s six (6)  highly qualified nominees to the Company&rsquo;s Board of Directors
(the &ldquo;Board&rdquo;). We believe the entire Board needs to be refreshed to ensure that (i) decisions relating to the Company&rsquo;s
strategic review are being made and (ii) the Company is being run, in a manner consistent with your best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After years of underperformance
and poor decision-making at Diffusion, we believe that stockholders have lost confidence in the Board&rsquo;s and management team&rsquo;s
ability and willingness to take the actions necessary to unlock value for stockholders. That is why we are seeking to replace the incumbent
Board with independent, highly qualified directors, who are committed to exploring all opportunities for value creation&mdash;including
by pursuing a sale of the whole Company&mdash;while serving the best interests of all stockholders in the boardroom. We believe that stockholders
would benefit from a new Board with independent directors who have extensive experience in serving as both operators and advisors to companies
in the healthcare industry &ndash; their expertise includes clinical development, public company operations, and proficiency in restructuring
and turnaround contexts. We believe that our nominees will provide perspective, industry experience, critically needed skill sets and,
most importantly, a shared objective of enhancing value for the benefit of all Diffusion stockholders. The individuals that we have nominated
are highly qualified, capable and ready to explore all options to best serve the interests of all stockholders of Diffusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the Company&rsquo;s
poor financial and longstanding stock price underperformance under the oversight of the Board, we strongly believe that the Board requires
new directors with the skills and expertise to ensure that the Company is configured and operated in a manner that maximizes value for
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently seven
(7) directors serving on the Board, all of whom have terms expiring at the Annual Meeting; however, the Company has disclosed that one
incumbent director will be retiring effective December 16, 2022 and will not be standing for reelection at the Annual Meeting and the
size of the Board will be reduced to six (6) directors effective and contingent upon such director&rsquo;s resignation. The Company has nominated
six (6) directors for election at the Annual Meeting. Through the attached Proxy Statement and enclosed BLUE proxy card, we are soliciting
proxies to, among other matters described in the Proxy Statement, elect our six (6) nominees, Jill Davidson, Tenzin Khangsar, Jeffrey
Kimbell, Jessica M. Lockett, Jeffrey Max and John S. Ziegler. The names, backgrounds and qualifications of the Company&rsquo;s nominees,
and other information about them, can be found in the Company&rsquo;s proxy statement. LifeSci and Diffusion will each be using a universal
proxy card for voting on the election of directors at the Annual Meeting, which will include the names of all nominees for election to
the Board. Stockholders will have the ability to vote for up to six (6) nominees on LifeSci&rsquo;s enclosed <B>BLUE </B>universal proxy
card. Any stockholder who wishes to vote for any combination of the Company nominees and our nominees may do so on LifeSci&rsquo;s <B>BLUE</B>
universal proxy card. <B>There is no need to use the Company&rsquo;s white proxy card or voting instruction form, regardless of how you
wish to vote. </B>In any case, we recommend that the stockholders vote in favor of LifeSci&rsquo;s nominees, who we believe are most qualified
to serve as directors in order to achieve a Board composition that we believe is in the best interest of all stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">i</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> We believe that voting on
the <B>BLUE</B> universal proxy card provides the best opportunity for stockholders to elect all of LifeSci&rsquo;s nominees and achieve
the best Board composition overall, since, according to the Company, any stockholder voting on the white proxy card that does not specify
how to vote with respect to any nominee will have their shares voted by the proxies &ldquo;for&rdquo; the Board&rsquo;s six nominees
for director. We therefore urge stockholders to use our <B>BLUE</B> universal proxy card to vote <B>&ldquo;FOR&rdquo; </B>our nominees.
<B>IMPORTANTLY, IF YOU MARK MORE THAN SIX &ldquo;FOR&rdquo; BOXES FOR THE ELECTION OF DIRECTORS, ALL OF YOUR VOTES FOR THE ELECTION OF
DIRECTORS WILL BE DEEMED INVALID.</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> We encourage you to carefully
consider the information contained in the attached Proxy Statement and then support our efforts by signing, dating and returning the
enclosed <B>BLUE</B> universal proxy card today. The attached Proxy Statement and the enclosed <B>BLUE</B> universal proxy card are first
being furnished to stockholders on or about ____________, 2022. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have already voted
for the incumbent management slate, you have every right to change your vote by signing, dating and returning a later dated <B>BLUE </B>universal
proxy card or by voting in person at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have any questions
or require any assistance with your vote, please contact InvestorCom LLC, which is assisting us, at its address and toll-free number listed
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">Thank you for your support,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">David Dobkin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">LifeSci Special Opportunities Master Fund Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"><BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">ii</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>If you have any questions, require assistance
in voting your BLUE universal proxy card,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>or need additional copies of LifeSci&rsquo;s
proxy materials,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>please contact InvestorCom LLC at the phone
numbers listed below.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 72px; width: 253px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">19 Old Kings Highway S. &ndash; Suite 130</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Darien, Connecticut 06820</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Toll Free (877) 972-0090</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Banks and Brokers call collect (203) 972-9300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">info@investor-com.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">iii</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>PRELIMINARY COPY SUBJECT TO COMPLETION<BR>
DATED <FONT STYLE="text-transform: uppercase">deceMBER 2</FONT>, 2022 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2022 ANNUAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>DIFFUSION
PHARMACEUTICALS INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>_________________________<BR>
<BR>
PROXY STATEMENT<BR>
OF<BR>
<FONT STYLE="text-transform: uppercase">LifeSci Special Opportunities Master Fund Ltd.</FONT><BR>
_________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLEASE SIGN, DATE AND MAIL THE ENCLOSED <U>BLUE
</U>UNIVERSAL PROXY CARD TODAY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci Special Opportunities
Master Fund Ltd., a Cayman Islands exempted company (&ldquo;LifeSci Master Fund&rdquo;, and, together with its affiliates named
herein, &ldquo;LifeSci&rdquo; or &ldquo;we&rdquo;), and the other participants in this solicitation are significant stockholders of Diffusion
Pharmaceuticals, Inc., a Delaware company (&ldquo;Diffusion&rdquo; or the &ldquo;Company&rdquo;), who beneficially own, in the aggregate,
96,976 shares of Common Stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), of the Company, representing approximately
4.8% of the outstanding shares of Common Stock. We believe that the Board of Directors of the Company (the &ldquo;Board&rdquo;) must be
replaced to ensure that the Board takes the necessary steps for the Company&rsquo;s stockholders to realize the maximum value of their
investment. We have nominated six (6) highly qualified directors who have strong, relevant backgrounds and who are committed to fully
exploring all opportunities to unlock and maximize stockholder value. Accordingly, we are seeking your support at the Company&rsquo;s
2022 Annual Meeting of Stockholders scheduled to be held by means of a live webcast on December 30, 2022 at [_:__] a.m., Eastern Time
(including any and all adjournments, postponements, continuations or reschedulings thereof, or any other meeting of stockholders held
in lieu thereof) (the &ldquo;Annual Meeting&rdquo;) for the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To elect LifeSci&rsquo;s six (6) director nominees, Jill Davidson, Tenzin Khangsar, Jeffrey Kimbell, Jessica M. Lockett, Jeffrey Max and John Ziegler (each a &ldquo;LifeSci Nominee&rdquo; and, collectively, the &ldquo;LifeSci Nominees&rdquo;) to serve as directors until the Company&rsquo;s next annual meeting of stockholders or until their respective successors are elected and qualified;</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To ratify the selection of KPMG LLP as the Company&rsquo;s independent registered public accounting firm for the year ending December 31, 2022;</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To approve, on an advisory basis, the compensation of the Company&rsquo;s named executive officers during the year ended December 31, 2021, as disclosed in the Company&rsquo;s proxy statement;</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Proxy Statement and the
enclosed <B>BLUE</B> universal proxy card are first being mailed to stockholders on or about __________, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has disclosed
that the Annual Meeting will be held exclusively online via a live webcast on the Internet. You will not be able to attend the Annual
Meeting in person at a physical location. To participate in the Annual Meeting, you must pre-register by following the instructions set
forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Registered Stockholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Company&rsquo;s
proxy statement, stockholders of record as of the record date may register to participate in the Annual Meeting remotely by visiting the
website [ ]. Please have your proxy card, or notice, containing your control number available and follow the instructions to complete
your registration request. After registering, stockholders will receive a confirmation email with a link and instructions for accessing
the virtual Annual Meeting. Requests to register to participate in the Annual Meeting remotely must be received no later than [ ] a.m.,
Eastern Time, on December [ ], 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Beneficial Stockholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Company&rsquo;s
proxy statement, stockholders whose shares are held through a broker, bank or other nominee as of the record date may register to participate
in the Annual Meeting remotely by visiting the website [ ]. Please have your Voting Instruction Form, notice, or other communication containing
your control number available and follow the instructions to complete your registration request. After registering, stockholders will
receive a confirmation email with a link and instructions for accessing the virtual Annual Meeting. Requests to register to participate
in the Annual Meeting remotely must be received no later than [ ] a.m., Eastern Time, on December [ ], 2022. If you are a beneficial stockholder
and you wish to vote your shares online during the virtual Annual Meeting, rather than submitting your voting instructions before the
Annual Meeting, you will need to contact your bank, broker or other nominee to obtain a legal proxy form that you will need to submit
electronically with your ballot during the online virtual Annual Meeting using a PDF, JPG, JPEG, GIF or PNG file format.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The meeting webcast will begin
promptly at [ ] a.m. Eastern Time and you should allow ample time for check-in procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has disclosed
that six (6) candidates can be elected to the Board at the Annual Meeting. Through the attached Proxy Statement and enclosed <B>BLUE</B>
universal proxy card, we are soliciting proxies to elect the LifeSci Nominees, who we believe are most qualified to serve as directors.
LifeSci and Diffusion will each be using a universal proxy card for voting on the election of directors at the Annual Meeting, which will
include the names of all nominees for election to the Board. Stockholders will have the ability to vote for up to six (6) nominees on
LifeSci&rsquo;s enclosed <B>BLUE</B> universal proxy card. Any stockholder who wishes to vote for any combination of the Company nominees
and the LifeSci Nominees may do so on LifeSci&rsquo;s <B>BLUE</B> universal proxy card. <B>There is no need to use the Company&rsquo;s
white proxy card or voting instruction form, regardless of how you wish to vote</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your vote to elect the LifeSci
Nominees will have the legal effect of replacing up to six (6) incumbent directors. If at least four (4) of our LifeSci Nominees are elected,
they will constitute a majority of the Board. There is no assurance that any of the Company&rsquo;s nominees will serve as directors if
all or some of the LifeSci Nominees are elected. The names, background and qualifications of the Company&rsquo;s nominees, and other information
about them, can be found in the Company&rsquo;s proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders are permitted
to vote for less than six (6) nominees or for any combination (up to six total) of the LifeSci Nominees and the Company&rsquo;s nominees
on the <B>BLUE</B> universal proxy card. We recommend that stockholders vote for the LifeSci Nominees. Among other potential consequences,
voting for Company nominees may result in the failure of several or all of the LifeSci Nominees to be elected to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> We believe that voting on
the <B>BLUE</B> universal proxy card provides the best opportunity for stockholders to elect the LifeSci Nominees and achieve the best
Board composition overall, since, according to the Company, any stockholder voting on the white proxy card that does not specify how
to vote with respect to any nominee will have their shares voted by the proxies &ldquo;for&rdquo; the Board&rsquo;s six nominees for
director. LifeSci therefore urges stockholders to use our <B>BLUE</B> universal proxy card to vote <B>&ldquo;FOR&rdquo;</B> the LifeSci
Nominees. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <B>OUR BLUE UNIVERSAL PROXY
CARD WILL BE VOTED AS DIRECTED. IF NO DIRECTION IS INDICATED WITH RESPECT TO HOW YOU WISH TO VOTE YOUR SHARES, THE PROXIES NAMED THEREIN
WILL VOTE SUCH SHARES &ldquo;FOR&rdquo; THE SIX (6) LIFESCI NOMINEES. IMPORTANTLY, IF YOU MARK MORE THAN SIX &ldquo;FOR&rdquo; BOXES
WITH RESPECT TO THE ELECTION OF DIRECTORS, ALL OF YOUR VOTES FOR THE ELECTION OF DIRECTORS WILL BE DEEMED INVALID.</B> <B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has set the close
of business on _______ as the record date for determining stockholders entitled to notice of and to vote at the Annual Meeting (the &ldquo;Record
Date&rdquo;). The address of the principal executive offices of the Company is 300 East Main Street, Suite 201, Charlottesville, Virginia
22902. Stockholders of record at the close of business on the Record Date will be entitled to vote at the Annual Meeting. According to
the Company, as of the Record Date, there were _______ shares of Common Stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof, LifeSci
Master Fund, LifeSci Special Opportunities Partners LP, a Delaware limited partnership (&ldquo;LifeSci Special Opportunities&rdquo;),
LifeSci Special Opportunities Offshore Fund, Ltd., a Cayman Islands exempted company (&ldquo;LifeSci Offshore&rdquo;), LifeSci Special
Opportunities Partners GP, LLC, a Delaware limited liability company (&ldquo;LifeSci GP&rdquo;), LifeSci Management Company LLC, a Delaware
limited liability company (&ldquo;LifeSci Management&rdquo;), Pirate Cove Capital Ltd., a Cayman Island exempted company (&ldquo;Pirate
Cove&rdquo;), David Dobkin and the LifeSci Nominees (each a &ldquo;Participant&rdquo; and, collectively, the &ldquo;Participants&rdquo;)
collectively beneficially own 96,976 shares of Common Stock (the &ldquo;LifeSci Shares&rdquo;). We intend to vote such shares <B>&ldquo;FOR&rdquo;</B>
the election of the LifeSci Nominees, <B>&ldquo;FOR&rdquo;</B> the approval of KPMG LLP as the Company&rsquo;s independent registered public accounting
firm for the year ending December 31, 2022 and <B>&ldquo;AGAINST&rdquo;</B> approval, on an advisory basis, of the compensation of the Company&rsquo;s
named executive officers, as described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We urge you to carefully consider
the information contained in this Proxy Statement and then support our efforts by signing, dating and returning the enclosed <B>BLUE</B>
universal proxy card today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS SOLICITATION IS BEING
MADE BY LIFESCI AND NOT ON BEHALF OF THE BOARD OR MANAGEMENT OF THE COMPANY. WE ARE NOT AWARE OF ANY OTHER MATTERS TO BE BROUGHT BEFORE
THE ANNUAL MEETING OTHER THAN AS SET FORTH IN THIS PROXY STATEMENT. SHOULD OTHER MATTERS, WHICH LIFESCI IS NOT AWARE OF A REASONABLE TIME
BEFORE THIS SOLICITATION, BE BROUGHT BEFORE THE ANNUAL MEETING, THE PERSONS NAMED AS PROXIES IN THE ENCLOSED <B>BLUE</B> UNIVERSAL PROXY
CARD WILL VOTE ON SUCH MATTERS IN THEIR DISCRETION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LIFESCI URGES YOU TO VOTE
 &ldquo;<B>FOR</B>&rdquo; THE LIFESCI NOMINEES BY FOLLOWING THE INSTRUCTIONS ON THE ENCLOSED <B>BLUE</B> UNIVERSAL PROXY CARD TODAY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PLEASE SIGN, DATE AND RETURN
THE <B>BLUE</B> UNIVERSAL PROXY CARD VOTING &ldquo;<B>FOR</B>&rdquo; THE ELECTION OF THE LIFESCI NOMINEES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IF YOU HAVE ALREADY SENT A
PROXY CARD FURNISHED BY COMPANY MANAGEMENT OR THE BOARD, YOU MAY REVOKE THAT PROXY AND VOTE ON EACH OF THE PROPOSALS DESCRIBED IN THIS
PROXY STATEMENT BY SIGNING, DATING AND RETURNING THE ENCLOSED <B>BLUE</B> UNIVERSAL PROXY CARD. THE LATEST DATED PROXY IS THE ONLY ONE
THAT WILL BE COUNTED. ANY PROXY MAY BE REVOKED AT ANY TIME PRIOR TO THE ANNUAL MEETING BY DELIVERING A WRITTEN NOTICE OF REVOCATION OR
A LATER DATED PROXY FOR THE ANNUAL MEETING OR BY VOTING IN PERSON AT THE ANNUAL MEETING.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Important Notice Regarding the Availability
of Proxy Materials for the Annual Meeting&mdash;This Proxy Statement and our BLUE universal proxy card are available at</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>www.___________.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMPORTANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Your vote is important,
no matter how many shares of Common Stock you own. LifeSci urges you to sign, date, and return the enclosed BLUE universal proxy card
today to vote FOR the election of the LifeSci Nominees and in accordance with LifeSci&rsquo;s recommendations on the other proposals on
the agenda for the Annual Meeting.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">If your shares of Common Stock are registered in your own name, please sign and date the enclosed <B>BLUE </B>universal proxy card and return it to LifeSci, c/o InvestorCom LLC, our proxy solicitor (&ldquo;InvestorCom&rdquo;), at 19 Old Kings Highway S., Suite 130, Darien, Connecticut 06820, in the enclosed postage-paid envelope today.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt">&#9744;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">If your shares of Common Stock are held in a brokerage account or bank, you are considered the beneficial owner of the shares of Common Stock, and these proxy materials, together with a <B>BLUE</B> voting form, are being forwarded to you by your broker or bank. As a beneficial owner, if you wish to vote, you must instruct your broker, trustee or other representative how to vote. Your broker cannot vote your shares of Common Stock on your behalf without your instructions. As a beneficial owner, you may vote the shares virtually at the Annual Meeting only if you obtain a legal proxy from the broker or bank giving you the rights to vote the shares.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt">&#9744;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Depending upon your broker or custodian, you may be able to vote either by toll-free telephone or by the Internet. Please refer to the enclosed voting form for instructions on how to vote electronically. You may also vote by signing, dating and returning the enclosed voting form.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">You may vote your shares virtually at the Annual Meeting. Even if you plan to attend the Annual Meeting virtually, we recommend that you submit your <B>BLUE</B> proxy card by mail by the applicable deadline so that your vote will be counted if you later decide not to attend the Annual Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As LifeSci is using a &ldquo;universal&rdquo;
proxy card, which includes the LifeSci Nominees as well as the Company&rsquo;s nominees, there is no need to use any other proxy card
regardless of how you intend to vote. <B>LifeSci strongly urges you NOT to sign or return any white proxy cards or voting instruction
forms that you may receive from the Company</B>. Even if you return the Company&rsquo;s white proxy card marked &ldquo;withhold&rdquo;
as a protest against the incumbent directors, it will revoke any proxy card you have previously sent to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>If you have any questions, require assistance
in voting your BLUE universal proxy card,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>or need additional copies of LifeSci&rsquo;s
proxy materials,</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>please contact InvestorCom  at the phone
numbers listed below.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 72px; width: 253px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">19 Old Kings Highway S. &ndash; Suite 130</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Darien, Connecticut 06820</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Toll Free (877) 972-0090</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Banks and Brokers call collect (203) 972-9300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">info@investor-com.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BACKGROUND TO THE SOLICITATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a chronology of events leading up to this proxy solicitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On August 6, 2021, LifeSci Master Fund was founded by Mr. Dobkin and first began researching the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On May 2, 2022, LifeSci Master Fund began acquiring its current position in the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On May 25, 2022, LifeSci Capital LLC (&ldquo;LS Capital&rdquo;), an independent investment bank, was engaged
by an unaffiliated client to serve as its representative in connection with presenting potential strategic alternatives to the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On May 26, 2022, Mr. Dobkin, in his capacity as a Managing Director of LS Capital, sent an email to Robert
Cobuzzi, the Company&rsquo;s President and Chief Executive Officer, and William Hornung, the Company&rsquo;s Chief Financial Officer,
to request a meeting to discuss potential strategic alternatives for the Company. Mr. Dobkin also made a call to the Company on behalf
of LS Capital&rsquo;s client requesting a call to discuss strategic alternatives.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Also on May 26, 2022, William Elder, the Company&rsquo;s general counsel, called Mr. Dobkin to discuss
the nature of the interest of LS Capital&rsquo;s client on a no-names basis.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On May 27, 2022, in response to Mr. Elder&rsquo;s call, Mr. Dobkin sent
an email to Mr. Elder which provided that LS Capital&rsquo;s client was interested in exploring several potential actions with the Company,
including, merging one or several new assets into the Company,</FONT> in <FONT STYLE="font-size: 10pt">which LS Capital&rsquo;s client
already has an interest, and would participate in providing additional financing, restructuring the Company to minimize cash burn, or
other strategic alternatives. LS Capital did not receive a response from the Company to its email.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On June 1, representatives of Tiberend Stategic Communications (&ldquo;Tiberend&rdquo;), the Company&rsquo;s
investor relations firm, attempted to call Mr. Dobkin but he was unable to immediately return their call. Mr. Dobkin called Tiberend representatives
over 15 times from June 1, to August 4, 2022 without any further response from Tiberend.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On August 4, 2022, Mr. Dobkin sent an email to
Mr. Elder to follow up on his email from May 27, 2022. Mr. Dobkin asked Mr. Elder if he was available for a phone call to further discuss
the email.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On August 4, 2022, Mr. Dobkin had a telephone call and corresponded via email with Daniel Boateng and
Jonathan Nugent of Tiberend. Mr. Dobkin requested help facilitating a call with Company management.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On September 14, 2022, Mr. Dobkin emailed Mr. Elder and Dr. Cobuzzi to once again follow up on his previous
outreach efforts. Mr. Dobkin stated that LS Capital would be very interested in speaking with the Company to explore strategic alternatives
that should result in a mutually beneficial outcome for all parties. Mr. Dobkin again requested a phone call to further discuss these
ideas.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On September 15, 2022, Mr. Boateng and Mr. Nugent of Tiberend sent an email to Mr. Dobkin at to arrange
a phone call to discuss the Company. Mr. Dobkin requested that a member of management be present on the call as well, but his request
was declined.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On September 16, 2022, Mr. Boateng and Mr. Nugent and Mr. Dobkin had a call to discuss various strategic
alternatives that LS Capital and its client-stockholders in the Company believed would be in the best interests of all of the Company&rsquo;s
stockholders. On this call, Mr. Dobkin requested to arrange a time to speak with the management of the Company following LS Capital&rsquo;s
and Tiberend&rsquo;s discussion of various strategic alternatives, including a potential merger with a private company or a sale of the
Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On September 21, 2022, nearly four months after Mr. Dobkin&rsquo;s initial outreach to the Company, Mr.
Dobkin emailed Mr. Boateng and Mr. Nugent as well as Mr. Elder and Dr. Cobuzzi to follow up on his request to schedule a phone call with
the Company&rsquo;s management.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On September 21, 2022, Mr. Elder requested that LS Capital&rsquo;s client disclose additional information
on a confidential basis and suggested that the parties execute a non-disclosure agreement. On the same day, Mr. Dobkin requested the Company&rsquo;s
non-disclosure agreement for review.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On September 23, 2022, Mr. Dobkin sent a follow-up via email to Mr. Elder requesting the Company&rsquo;s
non-disclosure agreement for review. Mr. Elder replied that the Company would return with a document shortly.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On September 26, 2022, Mr. Elder sent the Company&rsquo;s non-disclosure agreement via email to Mr. Dobkin.
Upon review of the non-disclosure agreement, LS Capital and certain of its affiliates declined to execute the non-disclosure agreement
due to various clauses in the agreement that would restrict transacting in the Company&rsquo;s stock and communications with third parties
regarding the Company on a multi-year basis that were not standard in LS Capital&rsquo;s view. Mr. Dobkin requested a follow-up call with
management and agreed to discuss business development opportunities with the Company in such a manner that would not require a non-disclosure
agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On September 27, 2022, Mr. Dobkin had a call with Mr. Elder, Mr. Boateng and Mr. Nugent, during which
potential business development opportunities were discussed and Mr. Dobkin identified three clients of LS Capital that had expressed interest
in a potential transaction with the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">From this point onward, the Company declined to engage in further communications with LS Capital or any
of its affiliates.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On October 16, 2022, LS Capital presented an unsolicited offer (the &ldquo;Offer&rdquo;) to the Company
on behalf of its client, an unaffiliated investor in the Company, to purchase 100% of the Company&rsquo;s outstanding common stock for
$6.58 per share in cash, which represented a 20% premium to the Company&rsquo;s closing stock price as of the close of business on Friday,
October 13, 2022.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On October 18, 2022, the Company acknowledged receipt of the Offer.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On October 19, 2022, Mr. Dobkin followed up with the Company on behalf of LS Capital&rsquo;s client regarding
the anticipated timing of the Company&rsquo;s response to the Offer.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On October 20, 2022, Mr. Elder replied to Mr. Dobkin, stating that the Company was continuing to work
through its evaluation of the Offer, but expected to have a response soon.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On October 25, 2022, the Company announced it had hired Canaccord Genuity (&ldquo;Canaccord&rdquo;), an
investment bank, to act as its financial advisor to oversee the process of exploring strategic alternatives for the Company. Mr. Elder
subsequently emailed a response letter on behalf of the Company to Mr. Dobkin regarding the Offer, which described the offer as &ldquo;woefully
inadequate&rdquo; and rejected the Offer, and directed further communications toward Canaccord as their financial advisor.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">On October 27, 2022 the Company filed a Current Report on Form 8-K with the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;) announcing that the Board had established December 16, 2022 as the date of the Annual Meeting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On November 7, 2022, LifeSci Master Fund delivered
a notice of nomination (the &ldquo;Nomination Notice&rdquo;) to the Company nominating the LifeSci Nominees as candidates for election
to the Board at the Annual Meeting. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On November 10, 2022, the Company filed a Current
Report on Form 8-K announcing that the Board had rescheduled the date of the Annual Meeting to December 30, 2022.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On November 17, 2022, LifeSci issued a press
release announcing its nomination of the LifeSci Nominees to the Board at the Annual Meeting.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On November 18, 2022, LifeSci Master Fund resubmitted
its notice of nomination to the Company to reflect certain updates to the Nomination Notice.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Also on November 18, 2022, the Company filed
its preliminary proxy statement. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&#183;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                            November 22, 2022, LifeSci Master Fund filed its preliminary proxy statement. </FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&#183;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                            November 28, 2022, the Company filed a revised preliminary proxy statement. </FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&#183;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                            December 1, 2022, the Company filed a revised preliminary proxy statement. </FONT> </TD></TR></TABLE>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/107% Calibri, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&#183;</FONT> </TD><TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                            December 2, 2022, LifeSci Master Fund filed this revised preliminary proxy statement.</FONT> </TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REASONS FOR THE SOLICITATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci Master Fund is a substantial
holder of Diffusion with extensive professional experience in the healthcare sector with expertise in supporting and advising clinical
stage biotech companies. After years of poor performance and decision-making, it is apparent to us that the Board and management team&rsquo;s
inability to effectively lead the Company has resulted in a significant loss of stockholder value. In our view, the current management
team and Board are unfit to undertake and oversee a strategic transaction that will unlock stockholder value. We believe that the LifeSci
Nominees are better qualified to lead efforts in overseeing a transaction to unlock stockholder value that the current Board and management
team has been unable to create.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>The Board and Management Team Have Overseen
Long-term Underperformance and Poor Shareholder Returns</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Diffusion&rsquo;s stock price has significantly
underperformed for years compared to macro and sector-specific indices demonstrating a lack of confidence in the Company&rsquo;s direction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="vertical-align: top; width: 44%; border-bottom: #7F7F7F 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 15%; border-bottom: #7F7F7F 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">6 Month Return</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 13%; border-bottom: #7F7F7F 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">2022 YTD Return</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 13%; border-bottom: #7F7F7F 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">One Year Return</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 15%; border-bottom: #7F7F7F 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">2020-Present Return</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: #7F7F7F 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Diffusion Pharmaceuticals Stock Price</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red"><B>-29.9%</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red"><B>-67.3%</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red"><B>-78.7%</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red"><B>-78.4%</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: #7F7F7F 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">S&amp;P 500</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-10.9%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-21.3%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-20.2%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #00B050">+15.1%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: #7F7F7F 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nasdaq Biotechnology Index</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #00B050">+6.6%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-13.6%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-21.4%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #00B050">+7.9%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: #7F7F7F 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">$400-$2,000M MC Biotech Index (n=235)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #00B050">+7.4%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-31.6%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-44.5%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-33.7%</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: #7F7F7F 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sub $400M MC Biotech Index (n=365)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-13.0%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-45.2%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-58.0%</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: red">-45.2%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<I>Source: Capital IQ as of 11/03/2022.
Custom indices reflect US listed biotech companies in designated market cap ranges at 12/31/2019 and adds in subsequent IPOs where the
post-money valuation falls in the market cap criteria</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On numerous occasions, the
Company received a warning from the Nasdaq Stock Market, LLC (&ldquo;Nasdaq&rdquo;) for lack of compliance with continued listing standards.
Specifically, the Company&rsquo;s stock price was unable to maintain the minimum $1.00 bid price required by the Nasdaq Capital Market
for continued listing on the exchange. As a result, multiple reverse stock splits were necessary to maintain the listing of its common
stock on the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 46%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 27%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Reverse Stock Split </B>&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ratio</B>&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; width: 27%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Approximate Reduction of Common Shares Outstanding</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Date</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">August 18, 2016</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1:10</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">93,200,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">December 13, 2018 </FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1:15</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">47,200,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">April 18, 2022</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1:50</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">100,000,000</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Source: Company press releases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company received a warning
from Nasdaq for lack of compliance with continued listing standards on May 29, 2020, but it regained compliance with the minimum bid price
requirement on June 1, 2020 without implementing a reverse split. On May 23, 2017, the Company received a minimum equity rule warning
from Nasdaq and subsequently announced that it had regained compliance with the minimum stockholder&rsquo;s equity requirement of $2.5
million on November 14, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Diffusion&rsquo;s Assets are Unlikely to
Produce Further Stockholder Value Under Current Management In Our View</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Although Diffusion has
spent over a decade attempting to develop its lead asset, Trans Sodium Crocetinate (TSC), across a broad spectrum of indications, in
our view it has yet to accomplish any sort of meaningful operational milestones other than the wasteful spending of immense cash resources
and a commensurate destruction of stockholder value. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has initiated
multiple phase 1, 2 and 3 trials over the last 15 years and has yet produce a single clinical read-out showing any statistical efficacy
for TSC or showing any clinical benefit whatsoever. In every clinical instance, the Company has either prematurely terminated its trial,
or failed to meet both the primary and secondary clinical end points previously investigated. TSC has been Phase 3 ready since 2015, but
the Board and management continue to run backwards in clinical development and run additional safety studies, for an asset that has already
been proven safe on multiple occasions. Furthermore, we believe the Company has not accurately and transparently reported their clinical
data, and, consequently, we have concerns the Company&rsquo;s leadership has not upheld its fiduciary duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> TSC has been in clinical
development for such a significant amount of time, that the Company&rsquo;s patents and intellectual property will (without obtaining
extensions) begin to expire within the next four years, rendering any additional development of the TSC asset pointless, an issue that
is incremental to our view that the likelihood of approval by the federal regulators has a very low probability. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company, in its own filings,
on multiple occasions over the last five years, has disclosed that it is actively seeking an investor/partner/buyer who has the ability
and desire to develop TSC, yet at no time has there been any indication that any investor/partner/buyer stepped forward. This seeming
complete lack of interest in TSC, in our view, is a clear statement on the perceived value of TSC and a reflection of the leadership&rsquo;s
mismanagement of the asset. We would expect that a Phase 3 ready asset, with any level of marketability should have been purchased by
a larger pharmaceutical company, especially given the Company&rsquo;s market capitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>We Believe Diffusion Has a Demonstrated Disregard
For Stockholders and a Long Track Record of Operational Shortcomings, Poor Capital Allocation Decisions and Dilutive Financings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Diffusion in its current form
became a public company in January 8, 2016 pursuant to a merger with its public company predecessor, RestorGenex Corporation. At the time,
the Company&rsquo;s clinical pipeline was primarily comprised of TSC, the same asset the Company is still developing today &ndash; nearly
seven years later:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT="Chart, bar chart&#10;&#10;Description automatically generated" STYLE="height: 193px; width: 410px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Source: Diffusion 10-K filing, 3/31/2017</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Company&rsquo;s
Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 31, 2017, Diffusion completed a Phase
1/2 Trial of TSC combined with first-line radiation and chemotherapy in patients newly diagnosed with primary brain cancer in 2015. Based
on those results and an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) in August 2015, the
Company developed guidelines for a pivotal Phase 3 registration study in GBM (<I>glioblastoma multiforme</I>). At the time, the Company
also planned to conduct trials of TSC in pancreatic cancer and metastatic brain cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> According to the Company&rsquo;s
Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on April 2, 2018, the Phase 3 INTACT trial
in GBM began enrollment in January 2018 &ndash; over two years after their meeting with the FDA. The Company also still planned to conduct
trials of TSC in pancreatic cancer, metastatic brain cancer, and added the development of a potential Phase 2 trial of TSC in the treatment
of acute ischemic stroke, as set forth below. We question why the Company was expending time and resources developing alternative indications
for TSC despite taking over two years to begin enrollment in the Phase 3 trial for treatment of GBM, the Company&rsquo;s leading indication
for TSC. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_004.jpg" ALT="A picture containing diagram&#10;&#10;Description automatically generated" STYLE="height: 255px; width: 413px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_005.jpg" ALT="A picture containing timeline&#10;&#10;Description automatically generated" STYLE="height: 252px; width: 410px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Source: Diffusion 10-K filing, 4/2/2018</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On
November 19, 2019, the Company presented data from the 19-patient, open-label, dose-escalation lead-in portion of its Phase 3 study of
TSC plus standard of care, and announced the presentation of additional data on December 10, 2019.<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-size: 10pt">Less
than a month later, the Company announced a $3.5 million registered direct offering, the third public offering it would complete that
year &ndash; totaling approximately $14.0 million in gross proceeds, which, among other things, diluted the holdings of the Company&rsquo;s
existing stockholders. In its amended press release announcing the transaction, the Company stated that &ldquo;[it] intends to use the
net proceeds from the offering, together with approximately $3.5 million the Company received from exercise of warrants since November
15, 2019, to fund research and development of its lead product candidate, TSC, including clinical trial activities, and for general corporate
purposes. Diffusion believes its cash and cash equivalents as of the date hereof, including the receipt of proceeds from the offerings,
are sufficient to fund operations for at least the next 12 months.&rdquo;<SUP>2</SUP></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 17, 2020, the Company
issued a press release regarding its 2019 financial results and business updates, including the commenced enrollment in its Phase 2 clinical
trial testing TSC for the treatment of acute stroke &ndash; PHAST-TSC (Pre-Hospital Administration of Stroke Therapy-TSC). The Company
also announced the issuance of two European patents for TSC in multiple indications, including in combination with tissue plasminogen
activator (tPA) to treat ischemic stroke &ndash; according to the Company, the only treatment approved by the FDA for the treatment of
stroke.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Despite the multiple 2019
capital raises to fund clinical development of TSC, the initiation of enrollment in the PHAST-TSC trial, and the statements by the Company
that cash resources were sufficient to continue operations for the next year, the Company quietly signaled that it was financially distressed
in various public communications. In its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on
March 17, 2020, the Company stated that, although it had designed and initiated a trial with the intention of enrolling 236 patients
in total across both a safety lead-in and a randomized section, &ldquo;commencement of enrollment in the randomization portion of the
INTACT Phase 3 Trial is contingent upon our entering into a strategic partnership providing the necessary resources to undertake the
full trial.&rdquo; Additionally, in its March 17, 2020 press release discussing its 2019 financial results and business update, the Company
stated, regarding its newly initiated PHAST-TSC Trial, &ldquo;We expect to complete the study and report topline data during 2022, subject
to receipt of adequate funding.&rdquo; Given the Company&rsquo;s multiple 2019 capital raises and its announcement just three months
earlier that it had sufficient funds to continue operations for at least the next 12 months, we question why the Company appeared to
suddenly lack the resources and/or funding to continue its development of TSC in these indications and, alternatively, why this need
was not previously disclosed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> On March 24, 2020, just six
days after issuing its revised press release discussing 2019 financial results and the commencement of its Phase 2 PHAST-TSC trial, the
Company issued a press release stating that it anticipated slowed enrollment in its trial in acute stroke due to the COVID-19 pandemic.
One week later, on April 1, 2020, the Company announced that it was evaluating TSC as a potential treatment for Acute Respiratory Distress
Syndrome (ARDS) in COVID-19 patients. Once again, we question why the Company was undertaking the evaluation of a new indication for
TSC despite its failure to progress the Phase 3 trial ready indication for GBM and its lack of resources to develop the alternative indications
for TSC that it already had in its pipeline. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 11, 2020, the Company
issued a press release discussing its first quarter 2020 financial results, and provided a business update. This included, among other
items, an announcement that the Company would expand its development of TSC to include COVID-19-related ARDS, and would pause its Phase
2 on-ambulance stroke trial due to enrollment delays. On September 10, 2020, the Company announced that it had dosed its first two patients
in its open-label Phase 1b lead-in trial of TSC in hospitalized COVID-19 patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>









<HR ALIGN="LEFT" SIZE="1" STYLE="width: 33%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1 </SUP>Company Press Releases, November 19, 2019 and December
10, 2019: https://investors.diffusionpharma.com/News/news-details/2019/Diffusion-Pharmaceuticals-Presents-Early-Findings-Showing-Increased-Survival-in-Lead-in-Portion-of-Phase-3-Glioblastoma-Study-with-TSC-plus-Standard-of-Care/default.aspx</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">https://investors.diffusionpharma.com/News/news-details/2019/Diffusion-Pharmaceuticals-Presents-Data-Suggesting-Optimized-TSC-Dosing-Regimen-Increases-Survival-in-Newly-Diagnosed-Inoperable-Glioblastoma-Patients/default.aspx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>
Company Press Release, December 12, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 11, 2020, the
Company issued a press release discussing its third quarter financial and operational results, including its announcement that it had
ended the quarter with $21.9 million in cash and equivalents on hand, which would sufficiently fund completion of its ongoing COVID-19
trials. Notably, unlike its press releases regarding the prior two quarters, the Company did not mention its ongoing GBM or stroke programs.
Its comments on these two programs can be found in the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on November 12,
2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0.5in; text-align: justify; text-indent: 0.5in"><I>&ldquo;[We]
determined we did not have the resources to support the randomized portion of the INTACT Trial. Further development of TSC in GBM is contingent
upon our ability to raise additional capital or enter into a strategic partnership.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0.5in; text-align: justify; text-indent: 0.5in"><I>&ldquo;Due
to, among other factors, the delays and other challenges related to COVID-19 discussed above under the heading &ndash;TSC in COVID-19,
and the substantial capital needs to complete the trial, we determined to begin winding down the PHAST-TSC Trial. Further development
of TSC in stroke is contingent upon our ability raise additional capital or enter into a strategic partnership.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> The Company quietly made the
decision to unceremoniously discontinue both of its ex-COVID developmental programs due to the anticipated expenses despite the comparatively
strong financial position of the Company at the time: &ldquo;<I>At quarter-close we had more than $25 million in cash, the largest cash
balance on hand since becoming a public company</I>&rdquo; &ndash; Ex-Chairman and CEO David Kalergis, Company Press Release dated August
10, 2020. Given the Company&rsquo;s record amount of cash on hand and that GBM was previously the leading indication for TSC in the Company&rsquo;s
pipeline, we question the motives for discontinuing the development of the GBM indication for TSC and why the Company&rsquo;s announcement
of its discontinuation of this developmental program was not disclosed in a more prominent manner. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 16, 2021, the
Company issued a press release announcing the completion of its Phase 1b study of TSC in hospitalized COVID-19 patients &ndash; &ldquo;<I>the
primary objective of the trial was to evaluate the safety and tolerability of TSC administered on a more frequent dosing regimen not previously
tested in a clinical trial setting. Secondary endpoints included pharmacokinetic measurement of TSC levels after dosing, relative improvements
in blood oxygen levels, and certain other clinical parameters related to COVID-19. Evaluation of secondary endpoint data is ongoing and
will be available early in the second quarter of 2021.&rdquo;</I> The Company also announced two additional clinical studies designed
to evaluate the efficacy of TSC &ndash; the TCOM (transcutaneous oximeter) study, a randomized, blinded, and placebo-controlled trial
to determine oxygen delivery in peripheral tissues versus placebo, and the DLCO study, which would measure the effects of TSC on the ability
of the lungs to transfer gas from inspired air to the bloodstream in patients with previously diagnosed interstitial lung disease. Both
of these studies were intended to provide dose-response data that the Company believed &ldquo;[would] guide its product and commercial
development strategies.&rdquo;<FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 18, 2021, the
Company issued a press release announcing the closing of an underwritten public offering, including full exercise of the underwriter&rsquo;s
option to purchase additional shares of common stock, resulting in total gross proceeds raised of approximately $34.5 million. The Company
stated that the proceeds of the offering would be used &ldquo;<I>to fund research and development of its lead product candidate, [TSC],
including the TCOM Study, the DLCO Study, and other clinical trial activities, and for general corporate purposes</I>.&rdquo;<FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>









<HR ALIGN="LEFT" SIZE="1" STYLE="width: 33%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3
</SUP></FONT>Company Press Release, February 16, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">https://investors.diffusionpharma.com/News/news-details/2021/Diffusion-Pharmaceuticals-Completes-Phase-1b-Study-of-TSC-in-Hospitalized-COVID-19-Patients/default.aspx</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4
</SUP></FONT>Company Press Release, February 18, 2021:</P>

<P STYLE="margin: 0pt 0">https://investors.diffusionpharma.com/News/news-details/2021/Diffusion-Pharmaceuticals-Announces-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares-of-Common-Stock/default.aspx</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On March 17, 2021, the
Company issued a press release discussing its 2020 financial results and provided a business update, including the planned initiation
of three additional trials (the &ldquo;Oxygenation Trials&rdquo;), which included the previously described TCOM and DLCO studies, as
well as its Hypoxia trial, which would evaluate the effects of TSC on maximal oxygen consumption (VO2) and partial pressure of blood
oxygen (PaO2) in healthy volunteers exposed to conditions that induce hypoxia. Once again, given the Company&rsquo;s mixed messaging
with respect to needing additional funds or a strategic partnership to further develop TSC for the indications already in the Company&rsquo;s
pipeline, we are unsure why the Company felt compelled to explore alternative indications for TSC at this juncture that would require
additional time and resources that the Company may or may not have had. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 10, 2021, the Company
issued a press release announcing final results from its Phase 1b trial of TSC in hospitalized COVID-19 patients, including its analysis
of secondary and exploratory endpoints. However, in a letter to stockholders, dated September 9, 2021 from CEO Dr. Cobuzzi, he disclosed
that &ldquo;<I>it is important to recall that the COVID-19 trial was designed as a safety and tolerability study only and was not designed
or powered to evaluate TSC&rsquo;s efficacy as a treatment for COVID-19.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 30, 2021, the Company
issued a press release announcing topline results from the TCOM trial of TSC:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&ldquo;<I>In this trial, transcutaneous oxygen
monitoring [] was used to measure the direct pharmacodynamic effects of TSC on peripheral tissue oxygenation in healthy normal volunteers.
Topline results were based upon analyses of primary endpoint data, which indicate, as compared to placebo, a positive dose-response trend
in TCOM readings after TSC administration that persisted through the measurement period. Due in part to the small number of healthy subjects
in each cohort, and the inherent variability of tcpO2 measurement, the magnitude of effect was not statistically significant; however,
the trends in the primary endpoint data indicated an improvement in peripheral oxygenation compared to placebo</I>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 10, 2021, the
Company issued a press release discussing its 2021 Q3 financial results and provided a business update, including announcing its intent
to further develop TSC, with hypoxic solid tumors as its next lead indication. The Company also stated its intent to dose the first subjects
in the Altitude trial and to initiate the ILD-DLCO trial later that year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 22, 2021, the
Company issued a press release announcing the dosing of its first participants in the Altitude trial. On December 16, 2021, the Company
issued a press release announcing the dosing of its first patients in its ILD-DLCO trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 23, 2022, the Company
issued a press release announcing topline results from the Altitude trial of TSC. Specific results included positive effects on lactate
and pH observed with a TSC 2.5 mg/kg dose versus the baseline measurement when compared to placebo (p &lt;0.1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 26, 2022, the Company
issued a press release announcing its intention to initiate a Phase 2 trial of TSC in patients with newly diagnosed glioblastoma, with
a planned initiation by end of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In its Quarterly Report on Form
10-Q, dated On August 12, 2022, the Company stated that &ldquo;<I>on August 9, 2022, in order to, among other things, dedicate more of
our human and other resources to [our GBM study] and our business development activities, as well as ongoing challenges enrolling patients
in clinical trials for respiratory indications during the ongoing COVID-19 pandemic, we made the decision to terminate recruitment and
enrollment in the ILD-DLCO Trial and begin winding the trial down.</I>&rdquo; The Company did not issue a press release regarding the
trial termination and did not disclose the trial termination in the press release dated August 11, 2022 reporting the second quarter
results and business update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> In our view, the Company&rsquo;s
actions as outlined above, which do not appear to us to be in the best interest of stockholders, are a cause for concern and demonstrate,
what we believe is, a track record of poor operational execution, capital allocation, transparency and leadership. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &nbsp; <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><I>It
                                            Appears to Us That the Company Has Failed to Generate Any Meaningful Value from TSC Since
                                            Going Public and We Believe the Board Cannot Be Trusted to Oversee the Company Going Forward</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B><I>&nbsp;</I></B> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We
                                            believe that the Company has failed to make any meaningful operational progress to further
                                            develop TSC and instead the Company has continuously eroded its cash balances and stockholder
                                            value with, what appear to us as, ill-conceived efforts to find alternative uses for TSC.
                                            The timeline set forth above demonstrates a prolonged track record of enormously deficient
                                            operational performance, poor capital allocation decisions, and a substantial lack of transparency
                                            with stockholders and the market and an utter disregard for the best interest of stockholders,
                                            in our view. We believe the points below represent certain significant operational missteps,
                                            poor capital allocation decisions, and other actions generally not in the best interest of
                                            stockholders: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiated a Phase 3 trial of TSC in GBM with
an intended total enrollment of 236 patients despite a well-known complete lack of funding to complete the full trial, resulting in a
tremendous waste of limited cash resources and a substantial operational opportunity cost. This resulted in the enrollment of only 19
patients in the lead-in portion of the trial, and did not produce any meaningful efficacy data. This trial was quietly discontinued approximately
one year later. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiated a Phase 2 trial of TSC in the treatment
of acute stroke that was intended to last for nearly three years across over 20 trial sites, despite knowingly having insufficient cash
reserves on the balance sheet to sustain the trial for the next twelve months. This trial was also quietly discontinued approximately
one year later due to the intensive capital requirements, once again representing a substantial opportunity cost and wasting limited cash
resources.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continuously raised capital numerous times in
quantities that were insufficient to support any meaningful operational progress beyond general and administrative spend, at the cost
of significant and punitive levels of dilution to stockholders. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Abandoned the Company&rsquo;s legacy TSC programs
in favor of developmental efforts around COVID-19-related indications, raising substantial capital around those programs, and failing
to produce any meaningful efficacy data in COVID-19 or to pursue the indication beyond the initial Phase 1b trial. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initiated multiple Phase 1 clinical trials (collectively
the &ldquo;Oxygenation Trials&rdquo;), which were described as central to the Company&rsquo;s &lsquo;core development strategy&rsquo;
to &ldquo;[provide] important additional data related to TSC dose and oxygenation as well as the mechanism of action&rdquo;<FONT STYLE="font-size: 10pt"><SUP>5</SUP></FONT>
 &ndash; despite the fact that TSC has been in late-stage development in similar indications since as early as 2009 &ndash; with such poor
trial design that two of the trials failed to meet statistical significance in key endpoints, and the third was quietly terminated early
(mention of which was buried in the Company&rsquo;s Quarterly Report on Form 10-Q). </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mystifyingly elected to move forward with development
of TSC in a new Phase 2 trial in GBM after previously abandoning an in-progress Phase 3 trial in the same indication, with the intention
of evaluating the &ldquo;safety and efficacy&rdquo; of TSC &ndash; even though the asset has been examined in numerous Phase 1 trials
within the past several years alone, including in GBM. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Repeatedly took actions that appeared to be intended
to obfuscate the Company&rsquo;s operational results to stockholders, including burying critical disclosures in SEC filings, rather than
in dedicated press releases or even in quarterly press releases discussing financial, operational, and business results and updates for
the period. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>









<HR ALIGN="LEFT" SIZE="1" STYLE="width: 33%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>5
</SUP></FONT>Company Press Release, September 9, 2021 &ndash; Letter to Shareholders:</P>

<P STYLE="margin: 0pt 0">https://investors.diffusionpharma.com/News/news-details/2021/Diffusion-Pharmaceuticals-Issues-Letter-to-Shareholders/default.aspx</P>

<P STYLE="margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Failed to generate any meaningful efficacy data
in any indication despite initiating a number of trials across a variety of therapeutic areas. The Company&rsquo;s management and Board
appear averse to pursuing any clinical research in any setting that evaluates TSC for any quality beyond safety. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s management
and Board have, in our view, consistently failed to generate any sort of meaningful positive value inflection for investors to date &ndash;
in fact, they have yet to even complete a single trial evaluating the efficacy of TSC despite raising tens of millions of dollars and
performing a variety of clinical trials across a spectrum of indications &ndash; with an asset that was Phase 3-ready in 2015. We believe
that they have not demonstrated the competence required to run a strategic process, including the business development efforts required
to salvage what little value remains for stockholders today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>The Board and Management Team Are Not Aligned
With Stockholders In Our View</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A significant majority of
the Board&rsquo;s and management team&rsquo;s respective ownership of Diffusion securities is represented by derivative securities granted
to them in connection with their employment at the Company or service on the Board. They collectively beneficially own only approximately
2.3% of the Company&rsquo;s outstanding shares according to the Company&rsquo;s proxy statement, only a small minority of which is represented
by actual direct holdings of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While Diffusion has continually
failed to deliver stockholder value, the poor stock performance is not felt by the Board or management team, as common equity makes up
a small amount of their total compensation. Such egregious misalignment between the Company leadership and stockholders is yet another
reason why we believe the Board and management team are unfit to lead efforts to deliver stockholder value as their de minimis positions
in the Company provide little incentive to effect the best transaction possible. As one of the largest Diffusion stockholders, LifeSci&rsquo;s
interests are aligned with the stockholder base, which is why we have nominated a slate of highly qualified directors who we believe will
explore all options to maximize value for stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>We Believe Our Nominees Are the Right Individuals
to Help Maximize Value for Diffusion Stockholders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> We do not believe the Board
has shown a commitment to maximizing value for the Company&rsquo;s stockholders. We have sought to engage with the Board on our views
and yet the Board has not appeared to take our concerns seriously. Despite the Company continually underperforming macro and industry
specific indices over many horizons, the Board appears to believe that the current leadership team can now unlock stockholder value that
it previously could not. We strongly believe that the current leadership of Diffusion are unworthy stewards of our Company and are not
qualified to lead the Company at this critical juncture. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are disappointed that,
in our engagement with the Company, the Board has actively resisted our ideas for creating stockholder value. For example, a client advised
by LS Capital offered to acquire all outstanding shares of the Company for $6.58 per share on October 16, 2022, representing a 20% premium
at the time of the offer and a 24% premium based on the closing price as of November 3, 2022, which was unceremoniously rejected by the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also do not believe the
Board&rsquo;s nor management&rsquo;s interests are adequately aligned with those of Diffusion&rsquo;s stockholders as most of the directors
and management own insignificant amounts of the Company&rsquo;s stock. In addition, we do not believe the track record of the current
Board should provide stockholders with confidence in the current leadership group&rsquo;s ability to create value or credibly to lead
a robust review of strategic alternatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In light of the issues we
have summarized herein and our unsuccessful attempts at engaging constructively with the Board to enact much-needed change, we have nominated
six independent and highly qualified director candidates who possess deep experience in the biotech industry and in finance, capital allocation,
corporate transactions, strategy and governance. We believe the LifeSci Nominees will bring much needed skillsets and experience to the
Board and will be able to guide the Company through an effective and efficient strategic review process as demonstrated by their biographies
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"><B><U>Jill Davidson</U></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Ms. Davidson has significant expertise in the pharmaceutical
industry and currently serves as the President of Fast Scripts LLC, an early-stage medical service provider to those recovering from
opioid addiction</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Previously, Ms. Davidson served in c-suite level roles at
medical care providers Omnicare, Inc. and Clasen Long Term Care Pharmacy. She was also the President of the Missouri-Illinois Gateway
Hemophilia Association and the Vice President of the National Pharmacy Roundtable.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Ms. Davidson is the Co-Manager of SkiProp LLC and the Manager
of Davidson LLC, which both own various rental properties.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"><B><U>Tenzin Khangsar</U></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Mr. Khangsar is the Principal at Snowlion Ventures, a Vancouver-based
financial consulting firm, and was previously an advisor to Deloitte Touche and a Managing Director and Executive Vice President for
RCI Capital Group.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Mr. Khangsar has served as an executive advisor for privately-held
emerging growth companies and publicly-traded corporations alike, advising on financial strategy and execution and organizational infrastructure
to support governance matters, among which include Google LLC, Key, Empower Clinics Inc. (CSE: CBDT) and Dapper Labs.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Mr. Khangsar also previously served in various government
roles in Canada&rsquo;s Office of the Prime Minister and the Minister of Immigration, including as Chief of Staff, and served as Honorary
Counsel to the Government of Mongolia, Chair of the Multicultural Advisory Committee of British Columbia and Director and President of
the Canada-India Business Council.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>He also previously served on the board of directors of Northstar
Trade Finance, a financial services provider, and Planterra, a non-profit dedicated to sustainable community development through travel,
and has significant experience serving in executive roles at non-profit organizations.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"><B><U>Jeffrey Kimbell</U></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Mr. Kimbell has extensive experience in the healthcare industry
as well as significant advisory and government experience, and he currently serves as the President of Jeffrey J. Kimbell &amp; Associates,
a client service provider to the life sciences industry.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Mr. Kimbell served on President George W. Bush&rsquo;s Transition
Team Advisory Committee for the U.S. Department of Health and Human Services.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Previously, he served as Founding Partner of Advyzom, LLC,
a leading boutique consulting company specializing in highly strategic regulatory and development advice and services for the pharmaceutical
and healthcare industries.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Mr. Kimbell previously served as the first Executive Director
of the Medical Device Manufacturers Association, one of the leading educational and advocacy association advancing the interests of innovative
and entrepreneurial medical device manufacturers in the United States.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"><B><U>Jessica M. Lockett</U></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Ms. Lockett currently serves as a Partner at Lockett + Horwitz,
PLC.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Ms. Lockett has extensive knowledge of the capital markets
and securities laws, and as a corporate and securities law attorney, she has experience representing public and private companies at
various stages of development with corporate governance and securities matters, as well as advising on mergers and acquisitions, financing,
and fundraising activities.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Ms. Lockett currently serves on the board of directors of
Ammo, Inc. (NASDAQ: POWW).</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"><B><U>Jeffrey Max</U></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Mr. Max has extensive experience as a c-suite level executive
across a variety of industries. He currently serves as the CEO of Ascent Solar Technologies, and previously served as CEO of Agile Space
Industries, Inc., Rezolve, Inc., Venda, Inc. and WhiteLight Systems, Inc., and as President of Powa Technologies, Inc.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Mr. Max currently serves as a director of Orbital Assembly
Corporation.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Mr. Max previously served as a Managing Partner of La Plata
Capital Partners, LLC, and as a Senior Advisor to Liiv Group, two investment-based companies.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Mr. Max also previously served as Managing Director PLR Advisors,
Ltd., a capital markets and technology consulting firm, and Executive Vice President of OptiMark Technologies Inc., a stock-trading technology
developer.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"><B><U>John Ziegler MD</U></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Dr. Ziegler is currently the Chief Medical Officer of Promedim
Ltd., a firm specializing in the oversight of pharmaceutical clinical trials, and also serves as the Managing Partner of Mountain Anesthesia
PLLC (d/b/a Premier Healthcare Partners).</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Dr. Ziegler has served as a consultant to the pharmaceutical
industry since 2012 and, in that capacity, has acted as the Medical Director of many clinical trials and drug development programs for
a number of pharmaceutical companies and clinical research organizations, and is also a Fellow of the American Society of Anesthesiologists.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD>Dr. Ziegler previously served on the board of directors of
LifeSci Acquisition Corp (formerly NASDAQ: LSAC).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">PROPOSAL NO.
1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ELECTION OF DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board is currently composed
of seven (7) directors, six (6) of whom will be standing for reelection at the Annual Meeting and one (1) of whom will not. We are seeking
your support at the Annual Meeting to elect our six (6) LifeSci Nominees, Jill Davidson, Tenzin Khangsar, Jeffrey Kimbell, Jessica M.
Lockett, Jeffrey Max and John Ziegler, for terms ending at the Company&rsquo;s 2023 annual meeting of stockholders (the &ldquo;2023 Annual
Meeting&rdquo;). Your vote to elect the LifeSci Nominees will have the legal effect of replacing the entire Board with the LifeSci Nominees.
If at least four (4) of our LifeSci Nominees are elected, they will represent a majority of the members of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Proxy Statement includes
the information required to be provided to the Company pursuant to the Universal Proxy Rules, including Rule 14a-19(a)(1) under the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). This proxy statement includes the names of all nominees for whom we
intend to solicit proxies. Further, we intend to solicit the holders of shares of Common Stock representing at least 67% of the voting
power of the shares of Common Stock entitled to vote on the election of directors in support of director nominees other than the Company&rsquo;s
nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE LIFESCI NOMINEES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following information
sets forth the name, age, business address, present principal occupation, and employment and material occupations, positions, offices,
or employments for the past five (5) years of each of the LifeSci Nominees. The nominations were made in a timely manner and in compliance
with the applicable provisions of the Company&rsquo;s governing instruments. The specific experience, qualifications, attributes and skills
that led us to conclude that the LifeSci Nominees should serve as directors of the Company are set forth above in the section entitled
 &ldquo;Reasons for the Solicitation&rdquo; and below. This information has been furnished to us by the LifeSci Nominees. All of the LifeSci
Nominees, other than Mr. Khangsar, are citizens of the United States. Mr. Khangsar is a citizen of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><B>Jill Davidson</B>, age
65, has served as President of Fast Scripts LLC, an early-stage medical service provider to those recovering from opioid addiction, since
March 2021; Co-Manager of SkiProp LLC, an owner of rental properties, since April 2015; and Manager of Davidson LLC, an owner of various
businesses and rental properties, since 1996. Previously, Ms. Davidson served as Vice President at Omnicare, Inc. (&ldquo;Omnicare&rdquo;),
a comprehensive pharmaceutical and chronic care service provider, from 1997 to 1999. Prior to that, she served as Chief Operating Officer
of Clasen Long Term Care Pharmacy, a medical services provider, from 1989 until it was acquired by Omnicare in 1997. Ms. Davidson has
previously served as President of the Missouri-Illinois Gateway Hemophilia Association, from 2002 to 2003, and Vice President of the National
Pharmacy Roundtable, from 1995 to 1996. Ms. Davidson received her B.A. in Pharmacy from the University of Kentucky, College of Pharmacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">We believe Ms. Davidson&rsquo;s
significant executive-level management experience in the medical services industry will make her a valuable addition to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><B>Tenzin Khangsar</B>, age
50, currently serves as Principal at Snowlion Ventures, a Vancouver-based financial consulting firm, a position he has held since 2014.
Mr. Khangsar has served as an executive advisor for privately-held emerging growth companies and publicly-traded corporations alike, advising
on financial strategy and execution and organizational infrastructure to support governance matters, among which include Google LLC, Alphabet
Inc.&rsquo;s (NASDAQ: GOOGL) internet and technology product development segment, since June 2020; Key, a real estate technology company,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in">since July 2020;
Empower Clinics Inc. (CSE: CBDT), a medical diagnostics and laboratory processing provider, since September 2020; and Dapper Labs, a
software developer harnessing blockchain technology to develop new forms of digital entertainment, since May 2020. Prior to that, Mr.
Khangsar served as an advisor at Deloitte Touch&eacute; Tohmatsu Limited, a global professional services firm, from 2014 to 2016, and
as Managing Director and Executive Vice President at RCI Capital Group Inc., an investment bank specializing in the energy and natural
resources sectors, from 2012 to 2014. Prior to that, he served in various government roles in Canada&rsquo;s Office of the Prime Minister
and the Minister of Immigration, including Chief of Staff, Senior Advisor, and Director, from 2006 to 2012. Mr. Khangsar served as Honorary
Counsel to the Government of Mongolia, from January 2016 to January 2020; Chair of the Multicultural Advisory Committee of British Columbia
from 2013 to 2016; and Director and President of the Canada-India Business Council in 2013. Earlier in his career, Mr. Khangsar worked
in the television and telecommunications sectors, including cofounding Invidex, a video transmission software developer, from 1999 to
2006, until it was acquired by Aldea Solutions Inc. (formerly Aldeavision Inc.), a leading provider of television and media services
in Canadian markets. He started his career as a sports journalist for CBC-TV, serving from 1993 to 1997. Mr. Khangsar previously served
on the board of directors of each of Northstar Trade Finance, a financial services provider, from 2015 to 2017, and Planeterra, a non-profit
organization dedicated to sustainable community development through travel, from January 2016 to January 2020. He also has significant
experience serving in executive roles at non-profit organizations. Since February 2020, he has served as the Chair of the board of trustees
for the Dalai Lama Center for Peace and Education and Buddha Without Borders. He received his Bachelor of Commerce, Finance and International
Business, from McGill University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">We believe Mr. Khangsar&rsquo;s
extensive knowledge of the capital markets and governance practices as a result of his investment experience and advisory expertise, will
make him a valuable addition to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"><B>Jeffrey Kimbell</B>, age
52, has served as President of Jeffrey J. Kimbell &amp; Associates (&ldquo;Kimbell &amp; Associates&rdquo;), a 16-person, 70-client service
provider to the life sciences industry based in Park City, Utah, and Washington, D.C., since 1998. Mr. Kimbell has also served as Co-Founder
and President of Magnum Entertainment Group, a full-service entertainment event planning firm, since 2004, and as Managing Director of
Jackalope Real Estate, LLC, an owner and operator of real estate, since 2001. Previously, he served as Founding Partner of Advyzom, LLC,
a leading boutique consulting company specializing in highly strategic regulatory and development advice and services for the pharmaceutical
and healthcare industries, from 2011 to 2014. Before establishing Kimbell &amp; Associates, Mr. Kimbell served as the first Executive
Director of the Medical Device Manufacturers Association, the leading educational and advocacy association advancing the interests of
innovative and entrepreneurial medical device manufacturers in the United States, from 1994 to 1998. Prior to that, Mr. Kimbell was a
Personal Aide to former U.S. Senator Howard H. Baker, Jr., Personal Attach&eacute; to former U.S. Secretary of State Lawrence S. Eagleburger,
and worked for former U.S. Congressman Sam Johnson. From 2001 to 2008, Mr. Kimbell served on President George W. Bush&rsquo;s Transition
Team Advisory Committee for the U.S. Department of Health and Human Services. Mr. Kimbell has served as an Advisor to the board of directors
of BioUtah, a life sciences trade association based in Utah, since January 2021. In addition, Mr. Kimbell previously served as Political
Action Committee Chairman of the Safari Club International (&ldquo;SCI&rdquo;), a wildlife conservation and game management organization,
and as Chairman of the SCI Hunter Defense Fund and as President of both the City Tavern Club of Washington and the Capital Club. Mr. Kimbell
received his B.A. in Political Science from Southern Methodist University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">We believe that Mr. Kimbell&rsquo;s
extensive experience in the pharmaceutical and healthcare industries and his significant advisory and government experience will make
him a valuable addition to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Jessica M. Lockett</B>,
age 36, currently serves as Partner at Lockett + Horwitz, PLC (f/k/a Horwitz + Armstrong, PLC), since January 2021, and served as an Associate
from August 2016 to January 2021. Ms. Lockett is a corporate and securities law attorney representing public and private companies at
various stages of development with corporate governance and securities matters, as well as advising on mergers and acquisitions, financing,
fundraising activities, and going-public transactions. Ms. Lockett currently serves on the board of directors of Ammo, Inc. (NASDAQ: POWW),
a leading producer of high performance ammunition and components, since December 2020. Ms. Lockett is an active member of the State Bar
of California. She received her B.A. in Psychology from the University of Arizona and her J.D., cum laude, from Thomas Jefferson School
of Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We belive Ms. Lockett&rsquo;s
extensive knowledge of the capital markets and securities laws, together with her public company board experience, will make her a valuable
addition to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Jeffrey Max</B>, age 65,
currently serves as Chief Executive Officer of Ascent Solar Technologies, Inc. (NASDAQ: ASTI), a solar technology and power solutions
provider, a position he has held since September 2022. Mr. Max also serves as Managing Partner of La Plata Capital Partners LLC, a privately
owned investment company, since March 2016, and as a Senior Advisor to Liiv Group, an investment firm headquartered in New York City with
portfolio companies providing media production, marketing, and advertising services, since June 2018. Previously, Mr. Max served as Chairman
and Chief Executive Officer of Agile Space Industries, Inc., an in-space propulsion solutions provider, specializing in additively manufactured
hypergolic chemical systems, from August 2019 to March 2022. Prior to that, Mr. Max was Chief Executive Officer of Rezolve, Inc., a mobile
commerce and mobile engagement firm, from March 2016 to July 2019. Prior to that, he was President of Powa Technologies, Inc., a mobile
commerce and ecommerce firm, from 2014 to 2016. Prior to that, Mr. Max was Chief Executive Officer of both Venda, Inc., an e-commerce
software as a service company, from 2003 to 2014, and of WhiteLight Systems, Inc., a data analytics company, from 2002 to 2003, until
it was acquired by SunGard Data Systems, a subsidiary of Fidelity National Information Services, Inc. (NYSE: FIS), in 2003. Earlier in
his career, Mr. Max served as a Managing Director at PLR Advisors, Ltd., a capital markets and technology consulting firm, from 2001 to
2002, and as an Executive Vice President at OptiMark Technologies Inc., a stock-trading technology developer, from 1997 to 2000. Mr. Max
currently serves on the board of directors of Orbital Assembly Corporation, an aviation and aerospace component manufacturer, since September
2022. Mr. Max received his B.A. from the University of California, Santa Cruz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that Mr. Max&rsquo;s
substantive experience from serving as chief executive officer at multiple private and public companies, as well as his board and leadership
experience, makes him well-suited to serve on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>John Ziegler MD</B>,
age 64, has served as a consultant to Harbor Clinical, a clinical biotechnology research services firm based in Boston,
Massachusetts, since July 2020, and as Chief Medical Officer of Promedim Ltd., a U.K.-based clinical research oversight firm
specializing in the oversight of pharmaceutical clinical trials, since 2016. Dr. Ziegler has also served as Managing Partner of
Mountain Anesthesia PLLC (d/b/a Premier Healthcare Partners (&ldquo;Premier Healthcare&rdquo;)), a full-service medical provider,
since 2010, and previously served in various management and senior level positions at a number of healthcare organizations since
1989, including as Critical Care Physician and Cardiac Anesthesiologist. Dr. Ziegler recently served on the board of directors of
LifeSci Acquisition Corp. (formerly NASDAQ: LSAC) (n/k/a, Vincerx Pharma, Inc. (NASDAQ: VINC)), a special purpose acquisition
company, from March 2020 to December 2020. He is also a Fellow of the American Society of Anesthesiologists. Dr. Ziegler received a
B.A. in both Biology and Chemistry from Indiana University, Bloomington, and his Doctorate in Medicine from Emory University School
of Medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that Dr. Ziegler&rsquo;s
over 30 years of experience in the healthcare and biotechnology industries, as well as his extensive leadership expertise, will make him
a valuable addition to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal business address
of Ms. Davidson is 1984 E Weber Canyon Road, PO Box 663, Oakley Utah 84055. The principal business address of Mr. Khangsar is 2149 Shafton
Place, West Vancouver, British Columbia, V7V 3B2. The principal business address of Mr. Kimbell is 950 Aerie Drive, Park City, Utah 84060.
The principal business address of Ms. Lockett is 2 South Pointe Ste. 275, Lake Forest, California 92630. The principal business address
of Mr. Max is 1071 S Lakeside Dr., Hesperus, Colorado 81326. The principal business address of Dr. Ziegler is 3088 Meadows Drive, Park
City, Utah 84060.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof, none
of the LifeSci Nominees own beneficially or of record any securities of the Company and none of the LifeSci Nominees have entered into
any transactions in securities of the Company during the past two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci believes that each
of the LifeSci Nominees presently is, and if elected as a director of the Company, each of the LifeSci Nominees would be, an &ldquo;independent
director&rdquo; within the meaning of applicable NASDAQ listing standards applicable to board composition, including Rule 5605(a)(2),
and Section 301 of the Sarbanes-Oxley Act of 2002. Notwithstanding the foregoing, LifeSci acknowledges that no director of a NASDAQ listed
company qualifies as &ldquo;independent&rdquo; under the NASDAQ listing standards unless the board of directors affirmatively determines
that such director is independent under such standards. Accordingly, LifeSci acknowledges that if any LifeSci Nominee is elected, the
determination of such LifeSci Nominee&rsquo;s independence under the NASDAQ listing standards ultimately rests with the judgment and discretion
of the Board. No LifeSci Nominee is a member of the Company&rsquo;s compensation, nominating or audit committee that is not independent
under any such committee&rsquo;s applicable independence standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than as stated herein,
there are no arrangements or understandings between or among any of the Participants or any other person or persons pursuant to which
the nomination of the LifeSci Nominees described herein is to be made, other than the consent by each of the LifeSci Nominees to be named
in this Proxy Statement and to serve as a director of the Company if elected as such at the Annual Meeting. None of the LifeSci Nominees
is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries
in any material pending legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If LifeSci Master Fund is
successful in obtaining stockholder approval for the election of three (3) or more of the Nominees at the Annual Meeting, then a change
of control of the Board may be deemed to have occurred under certain of the Company&rsquo;s material contracts. Based on a review of the
Company&rsquo;s material contracts and agreements, such a change of control may trigger certain change of control provisions or payments
contained therein as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Company&rsquo;s
Employment Agreements (the &ldquo;Employment Agreements&rdquo;), entered into between the Company and its executive officers, including
Dr. Cobuzzi, Dr. Galloway, Ms. Jaeger and Messrs. Hornung and Elder, a change of control will be deemed to have occurred if, among other
things, during any period of 12 consecutive months, the individuals who, at the beginning of such period, constitute the Board, and any
new director whose election by the Board or nomination for election by the Company&rsquo;s stockholders was approved by a vote of at least
two-thirds of the directors then still in office who either were directors at the beginning of the 12-month period or whose election or
nomination for election was previously so approved, cease for any reason to constitute at least a majority of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that LifeSci
is successful in electing three (3) or more of the LifeSci Nominees, a change of control under the Employment Agreements could be triggered,
however, the change of control provisions under the Employment Agreements are double-trigger provisions, meaning that a change of control
in and of itself does not trigger any payments or benefits under the Employment Agreements, but rather there would also need to be a qualifying
termination of the affected executives or resignation for &ldquo;good reason&rdquo; before any additional or accelerated obligations are
triggered. Specifically, under the Employment Agreements, executive officers are entitled to change of control payments and severance
benefits in the event that there is a change of control of the Company and, (A) within 24 months following a change of control or (B)
within 60 days prior to a change of control, either the executive resigns for good reason or the executive experiences an involuntary
termination of employment for reasons other than cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, under the terms of
the stock option agreements with the Company&rsquo;s named executive officers, upon a completion of a &ldquo;change of control&rdquo;
(as defined in the Company&rsquo;s 2015 Equity Incentive Plan (the &ldquo;2015 Plan&rdquo;)), options held by the Company&rsquo;s named
executive officers will become immediately vested and remain exercisable through their expiration date regardless of whether the holder
remains in the employment or service of the Company after the change of control. Alternatively, in connection with a change of control,
the Compensation Committee may, in its sole discretion, cash out the options. Under the 2015 Plan, a change in control occurs if, among
other things, during any period of 12 consecutive months, the individuals who, at the beginning of such period, constitute the Board,
and any new director whose election by the Board or nomination for election by the Company&rsquo;s stockholders was approved by a vote
of at least two-thirds of the directors then still in office who either were directors at the beginning of the 12-month period or whose
election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci has not independently
verified if the copies of the agreements publicly filed by the Company with the SEC and discussed above (collectively, the &ldquo;Company
Agreements&rdquo;) are the same as the actual executed copies of the agreements, and the analyses above are based on our review of the
Company&rsquo;s public SEC filings. While we are not aware of any, there may be other agreements that may be triggered by a change of
control in connection with the nomination and/or election of the Nominees. The discussion of the potential impact of the nomination is
based entirely upon our review of the Company Agreements. Notwithstanding the foregoing, LifeSci would expect the Board, consistent with
its fiduciary duties, to take any and all action necessary to render inapplicable any change of control provision that would be triggered
by the nomination and/or election of the LifeSci Nominees under the Company Agreements, as necessary and to the extent applicable and
permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> According to the Company,
the Board has approved the nomination of each LifeSci Nominee for election at the 2022 Annual Meeting for the purpose of avoiding triggering
any change of control provision under the Company Agreements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in this
Proxy Statement (including the Schedules hereto), (i) during the past 10 years, no LifeSci Nominee has been convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors); (ii) no LifeSci Nominee directly or indirectly beneficially owns any securities
of the Company; (iii) no LifeSci Nominee owns any securities of the Company which are owned of record but not beneficially; (iv) no LifeSci
Nominee has purchased or sold any securities of the Company during the past two years; (v) no part of the purchase price or market value
of the securities of the Company owned by any LifeSci Nominee is represented by funds borrowed or otherwise obtained for the purpose of
acquiring or holding such securities; (vi) no LifeSci Nominee is, or within the past year was, a party to any contract, arrangements or
understandings with any person with respect to any securities of the Company, including, but not limited to, joint ventures, loan or option
arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits, or the giving or withholding
of proxies; (vii) no associate of any LifeSci Nominee owns beneficially, directly or indirectly, any securities of the Company; (viii)
no LifeSci Nominee owns beneficially, directly or indirectly, any securities of any parent or subsidiary of the Company; (ix) no LifeSci
Nominee or any of his or her associates was a party to any transaction, or series of similar transactions, since the beginning of the
Company&rsquo;s last fiscal year, or is a party to any currently proposed transaction, or series of similar transactions, to which the
Company or any of its subsidiaries was or is to be a party, in which the amount involved exceeds $120,000; (x) no LifeSci Nominee or any
of his or her associates has any arrangement or understanding with any person with respect to any future employment by the Company or
its affiliates, or with respect to any future transactions to which the Company or any of its affiliates will or may be a party; (xi)
no LifeSci Nominee has a substantial interest, direct or indirect, by securities holdings or otherwise in any matter to be acted on at
the Annual Meeting; (xii) no LifeSci Nominee holds any positions or offices with the Company; (xiii) no LifeSci Nominee has a family relationship
with any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer; and (xiv)
no companies or organizations, with which any of the LifeSci Nominees has been employed in the past five years, is a parent, subsidiary
or other affiliate of the Company. There are no material proceedings to which any LifeSci Nominee or any of his or her associates is a
party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries.
With respect to each of the LifeSci Nominees, none of the events enumerated in Item 401(f)(1)-(8) of Regulation S-K of the Exchange Act
occurred during the past 10 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect that any
of the LifeSci Nominees will be unable to stand for election, but, in the event any LifeSci Nominee is unable to serve or for good cause
will not serve, the shares of Common Stock represented by the enclosed <B>BLUE</B> universal proxy card will be voted for substitute nominee(s),
to the extent this is not prohibited under the Company&rsquo;s Bylaws, as amended (the &ldquo;Bylaws&rdquo;) and applicable law. In addition,
we reserve the right to nominate substitute person(s) if the Company makes or announces any changes to the Bylaws or takes or announces
any other action that has, or if consummated would have, the effect of disqualifying any LifeSci Nominee, to the extent this is not prohibited
under the Bylaws and applicable law. In any such case, shares of Common Stock represented by the enclosed <B>BLUE</B> universal proxy
card will be voted for such substitute nominee(s). We reserve the right to nominate additional person(s), to the extent this is not prohibited
under Diffusion&rsquo;s organizational documents and applicable law, if Diffusion increases the size of the Board above its existing size.
Additional nominations made pursuant to the preceding sentence are without prejudice to our position that any attempt to increase the
size of the current Board or to classify the Board constitutes an unlawful manipulation of the Company&rsquo;s corporate machinery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci and Diffusion will
each be using a universal proxy card for voting on the election of directors at the Annual Meeting, which will include the names of all
nominees for election to the Board. Each of the LifeSci Nominees has consented to being named as a nominee for election as a director
of the Company in a proxy statement relating to the Annual Meeting. Stockholders will have the ability to vote for up to six (6) nominees
on LifeSci&rsquo;s enclosed <B>BLUE</B> universal proxy card. Any stockholder who wishes to vote for any combination of the Company&rsquo;s
nominees and the LifeSci Nominees may do so on LifeSci&rsquo;s enclosed <B>BLUE</B> universal proxy card. There is no need to use the
Company&rsquo;s white proxy card or voting instruction form, regardless of how you wish to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has disclosed
that six (6) candidates can be elected to the Board at the Annual Meeting. We are soliciting proxies to elect the LifeSci Nominees. Certain
information about the Company&rsquo;s nominees is set forth in the Company&rsquo;s proxy statement. LifeSci is not responsible for the
accuracy or completeness of any information provided by or relating to Diffusion or its nominees contained in any proxy solicitation materials
filed or disseminated by, or on behalf of, Diffusion or any other statements that Diffusion or its representatives have made or may otherwise
make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders are permitted
to vote for less than six (6) nominees or for any combination (up to six total) of the LifeSci Nominees and the Company&rsquo;s nominees
on the <B>BLUE</B> universal proxy card. <B>IMPORTANTLY, IF YOU MARK MORE THAN SIX &ldquo;FOR&rdquo; BOXES WITH RESPECT TO THE ELECTION
OF DIRECTORS, ALL OF YOUR VOTES FOR THE ELECTION OF DIRECTORS WILL BE DEEMED INVALID</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>WE STRONGLY URGE YOU TO VOTE
 &ldquo;FOR&rdquo; THE ELECTION OF THE LIFESCI NOMINEES ON THE ENCLOSED BLUE UNIVERSAL PROXY CARD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROPOSAL NO. 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">As
discussed in further detail in the Company&rsquo;s proxy statement, the Audit Committee has selected KPMG LLP (&ldquo;KPMG&rdquo;) as
the Company&rsquo;s independent registered public accounting firm for the fiscal year ending December 31, 2022. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">As
discussed in the Company&rsquo;s proxy statement, neither the Bylaws nor Diffusion&rsquo;s other governing documents or law require stockholder
ratification of the selection of KPMG as the Company&rsquo;s independent registered public accounting firm. According to the Company&rsquo;s
proxy statement, if the stockholders fail to ratify the selection, the Audit Committee will reconsider whether or not to retain that firm.
Even if the selection is ratified, the Audit Committee, in its discretion, may direct the appointment of different independent auditors
at any time during the year if they determine that such a change would be in the Company&rsquo;s best interests and the best interests
of the Company&rsquo;s stockholders. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WE MAKE NO RECOMMENDATION WITH RESPECT TO RATIFICATION
OF THE SELECTION OF KPMG LLP AS THE COMPANY&rsquo;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2022,
AND INTEND TO VOTE OUR SHARES &ldquo;FOR&rdquo; THIS PROPOSAL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROPOSAL NO. 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADVISORY VOTE ON EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed in further detail
in the Company&rsquo;s proxy statement, the Board is providing the Company&rsquo;s stockholders with an advisory vote on executive compensation
pursuant to the Dodd-Frank Act Wall Street Reform and Consumer Protection Act of 2010 and Section 14A of the Exchange Act. This advisory
vote, commonly known as a &ldquo;say-on-pay&rdquo; vote, is an annual, non-binding vote on the compensation paid to the Company&rsquo;s
named executive officers as described in the Company&rsquo;s proxy statement under the heading &ldquo;Executive Compensation&rdquo;, including
the Summary Compensation Table and the other related tables and narrative disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is requesting
stockholder approval of the compensation of the Company&rsquo;s named executive officers as disclosed in the Company&rsquo;s proxy statement.
This &ldquo;say-on-pay&rdquo; vote gives stockholders the opportunity to express their views on the Company&rsquo;s executive compensation.
The vote is not intended to address any specific item of compensation, but rather the overall compensation of the Company&rsquo;s named
executive officers and the compensation philosophy, policies and practices described in the Company&rsquo;s proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, the Company is
asking stockholders to vote for the following resolution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;RESOLVED, that the
stockholders of Diffusion Pharmaceuticals Inc. hereby approve, on an advisory basis, the compensation paid to the named executive officers
during the year ended December 31, 2021, as described in this Proxy Statement pursuant to the compensation disclosure rules of the Securities
and Exchange Commission, including the &ldquo;<I>Executive Compensation</I>&rdquo; section, the Summary Compensation Table and the other
related tables and narrative disclosure.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Company&rsquo;s
proxy statement, as this is an advisory vote, the outcome of the vote is not binding on the Company with respect to future executive compensation
decisions, including those relating to the Company&rsquo;s named executive officers, or otherwise. However, the Compensation Committee
and the Board will take into account the outcome of the vote when considering future executive compensation decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WE MAKE NO RECOMMENDATION WITH RESPECT TO THE
APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO THE COMPANY&rsquo;S NAMED EXECUTIVE OFFICERS, AS DESCRIBED IN THE COMPANY&rsquo;S
PROXY STATEMENT, AND INTEND TO VOTE OUT SHARES &ldquo;AGAINST&rdquo; THIS PROPOSAL.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">VOTING AND PROXY PROCEDURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each stockholder is entitled
to one vote per share of Common Stock held on all matters submitted to a vote of stockholders. Only stockholders of record on the Record
Date will be entitled to notice of and to vote at the Annual Meeting. Stockholders who sell their shares of Common Stock before the Record
Date (or acquire them without voting rights after the Record Date) may not vote such shares of Common Stock. Stockholders of record on
the Record Date will retain their voting rights in connection with the Annual Meeting even if they sell such shares of Common Stock after
the Record Date. Based on publicly available information, LifeSci believes that the only outstanding class of securities of the Company
entitled to vote at the Annual Meeting is the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shares of Common Stock represented
by properly executed <B>BLUE</B> universal proxy cards will be voted at the Annual Meeting as marked and, in the absence of specific instructions,
will be voted <B>FOR</B> the election of the LifeSci Nominees to the Board, <B>FOR</B> the ratification of the selection of KPMG as the
Company&rsquo;s independent registered public accounting firm for the fiscal year ending December 31, 2022, <B>AGAINST</B> approval, on
an advisory basis, of the compensation of the Company&rsquo;s named executive officers during the year ended December 31, 2021, as disclosed
in the Company&rsquo;s proxy statement, and in the discretion of the persons named as proxies on all other matters as may properly come
before the Annual Meeting, as described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has disclosed
that six (6) candidates can be elected to the Board at the Annual Meeting. We are soliciting proxies to elect the six (6) LifeSci Nominees.
LifeSci and Diffusion will each be using a universal proxy card for voting on the election of directors at the Annual Meeting, which will
include the names of all nominees for election to the Board. Stockholders will have the ability to vote for up to six (6) nominees on
LifeSci&rsquo;s enclosed <B>BLUE</B> universal proxy card. Any stockholder who wishes to vote for any combination of the Company&rsquo;s
nominees and the LifeSci Nominees may do so on LifeSci&rsquo;s <B>BLUE</B> universal proxy card. <B>There is no need to use the Company&rsquo;s
white proxy card or voting instruction form, regardless of how you wish to vote</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Stockholders are permitted
to vote for less than six (6) nominees or for any combination (up to six total) of the LifeSci Nominees and the Company&rsquo;s nominees
on the <B>BLUE</B> universal proxy card. We believe that voting on the <B>BLUE</B> universal proxy card provides the best opportunity
for stockholders to elect all of the LifeSci Nominees and achieve the best Board composition overall, since, according to the Company,
any stockholder voting on the white proxy card that does not specify how to vote with respect to any nominee will have their shares voted
by the proxies &ldquo;for&rdquo; the Board&rsquo;s six nominees for director. LifeSci therefore urges stockholders to use our <B>BLUE
</B>universal proxy card to vote <B>&ldquo;FOR&rdquo;</B> the six LifeSci Nominees. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> <B>OUR BLUE UNIVERSAL PROXY
CARD WILL BE VOTED AS DIRECTED. IF NO DIRECTION IS INDICATED WITH RESPECT TO HOW YOU WISH TO VOTE YOUR SHARES, THE PROXIES NAMED THEREIN
WILL VOTE SUCH SHARES &ldquo;FOR&rdquo; THE SIX (6) LIFESCI NOMINEES. IMPORTANTLY, IF YOU MARK MORE THAN SIX &ldquo;FOR&rdquo; BOXES
WITH RESPECT TO THE ELECTION OF DIRECTORS, ALL OF YOUR VOTES FOR THE ELECTION OF DIRECTORS WILL BE DEEMED INVALID. </B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>VIRTUAL MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has disclosed
that the Annual Meeting will be held exclusively online via a live webcast on the Internet. You will not be able to attend the Annual
Meeting in person at a physical location. To participate in the Annual Meeting, you must pre-register by following the instructions set
forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The meeting webcast will begin promptly at [ ]
a.m. Eastern Time and you should allow ample time for check-in procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Registered Stockholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According
                                            to the Company&rsquo;s proxy statement, stockholders of record as of the Record Date may
                                            register to participate in the Annual Meeting remotely by visiting the website [ ]. Please
                                            have your proxy card, or notice, containing your control number available and follow the
                                            instructions to complete your registration request. After registering, stockholders will
                                            receive a confirmation email with a link and instructions for accessing the virtual Annual
                                            Meeting. Requests to register to participate in the Annual Meeting remotely must be received
                                            no later than [ ] a.m., Eastern Time, on December [ ], 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Beneficial Stockholders</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Company&rsquo;s
proxy statement, stockholders whose shares are held through a broker, bank or other nominee as of the Record Date may register to participate
in the Annual Meeting remotely by visiting the website [ ]. Please have your Voting Instruction Form, notice, or other communication containing
your control number available and follow the instructions to complete your registration request. After registering, stockholders will
receive a confirmation email with a link and instructions for accessing the virtual Annual Meeting. Requests to register to participate
in the Annual Meeting remotely must be received no later than [ ] a.m., Eastern Time, on December [ ], 2022. If you are a beneficial stockholder
and you wish to vote your shares online during the virtual Annual Meeting, rather than submitting your voting instructions before the
Annual Meeting, you will need to contact your bank, broker or other nominee to obtain a legal proxy form that you will need to submit
electronically with your ballot during the online virtual Annual Meeting using a PDF, JPG, JPEG, GIF or PNG file format.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">QUORUM; BROKER NON-VOTES; DISCRETIONARY VOTING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A quorum is the minimum number
of shares of Common Stock that must be represented at a duly called meeting in person or by proxy in order to legally conduct business
at the meeting under the Bylaws and Delaware law. For the Annual Meeting, the presence, virtually or by proxy, of the holders of 33.4%
of the outstanding shares of Common Stock as of the Record Date will constitute a quorum for the transaction of business at the Annual
Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abstentions are counted as
present and entitled to vote for purposes of determining a quorum. Shares represented by &ldquo;broker non-votes&rdquo; also are counted
as present and entitled to vote for purposes of determining a quorum. However, if you hold your shares in street name and do not provide
voting instructions to your broker, your shares will not be voted on any proposal on which your broker does not have discretionary authority
to vote (a &ldquo;broker non-vote&rdquo;). Under applicable rules, your broker will not have discretionary authority to vote your shares
at the Annual Meeting on any of the proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a stockholder of
record, you must deliver your vote by mail or attend the Annual Meeting virtually and vote in order to be counted in the determination
of a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a beneficial owner,
your broker will vote your shares pursuant to your instructions, and those shares will count in the determination of a quorum. Brokers
do not have discretionary authority to vote on any of the proposals at the Annual Meeting. Accordingly, unless you vote via the <B>BLUE</B>
universal proxy card or provide instructions to your broker, your shares of Common Stock will count for purposes of attaining a quorum,
but will not be voted on the proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">VOTES REQUIRED FOR APPROVAL</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Election of Directors </I>&boxh;
According to the Company&rsquo;s proxy statement, directors are elected by a plurality vote. As a result, the six director nominees receiving
the greatest number of &ldquo;FOR&rdquo; votes will be elected as directors. If you vote &ldquo;FOR&rdquo; less than six (6) nominees in
Proposal No. 1, your shares will only be voted &ldquo;FOR&rdquo; those nominees you have so marked. If you vote &ldquo;FOR&rdquo; more
than six (6) nominees, all of your votes on Proposal No. 1 will be invalid and will not be counted. Abstentions, withhold votes, and any
broker non-votes will have no direct effect on the outcome of the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Ratification of Selection
of Independent Registered Public Accounting Firm &boxh; </I>According to the Company&rsquo;s proxy statement, the affirmative vote of
the holders of a majority of shares present virtually or represented by proxy and entitled to vote on the proposal is required to ratify
the selection of KPMG. The Company has indicated that abstentions will be counted as votes &ldquo;AGAINST&rdquo; this proposal. Broker-non-votes
will not be counted as votes cast and will have no effect on the result of the vote on this proposal<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Advisory Vote on Executive
Compensation &boxh; </I>According to the Company&rsquo;s proxy statement, with respect to the advisory vote on executive compensation,
in order to be approved, this proposal must receive the affirmative vote of the holders of a majority of shares present virtually or represented
by proxy and entitled to vote. The Company has indicated that abstentions will be counted as votes &ldquo;AGAINST&rdquo; this proposal.
Broker-non-votes will not be counted as votes cast and will have no effect on the result of the vote on this proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable Delaware
law, appraisal rights are not applicable to the voting on any matter to be considered at the Annual Meeting. If you sign and submit your
<B>BLUE</B> universal proxy card without specifying how you would like your shares voted, your shares will be voted in accordance with
LifeSci&rsquo;s recommendations specified herein and in accordance with the discretion of the persons named on the <B>BLUE </B>universal
proxy card with respect to any other matters that may be voted upon at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">REVOCATION OF PROXIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders of the Company
may revoke their proxies at any time prior to the completion of voting at the Annual Meeting by attending the Annual Meeting and voting
in person (although, attendance at the Annual Meeting will not in and of itself constitute revocation of a proxy), by delivering a written
notice of revocation, or by signing and delivering a subsequently dated proxy which is properly completed. The latest dated proxy is the
only one that will be counted. The revocation may be delivered either to LifeSci in care of InvestorCom at the address set forth on the
back cover of this Proxy Statement or to the Company at 300 East Main Street, Suite 201, Charlottesville, Virginia 22902, or any other
address provided by the Company. Although a revocation is effective if delivered to the Company, we request that either the original or
photostatic copies of all revocations be mailed to LifeSci in care of InvestorCom at the address set forth on the back cover of this Proxy
Statement so that we will be aware of all revocations and can more accurately determine if and when proxies have been received from the
holders of record on the Record Date of a majority of the shares entitled to be voted at the Annual Meeting. Additionally, InvestorCom
may use this information to contact stockholders who have revoked their proxies in order to solicit later dated proxies for the election
of the LifeSci Nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IF YOU WISH TO VOTE FOR THE LIFESCI NOMINEES,
PLEASE SIGN, DATE AND RETURN THE ENCLOSED BLUE UNIVERSAL PROXY CARD TODAY IN THE POSTAGE-PAID ENVELOPE PROVIDED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SOLICITATION OF PROXIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The solicitation of proxies
pursuant to this Proxy Statement is being made by LifeSci. Proxies may be solicited by mail, facsimile, telephone, Internet, in person
and by advertisements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci Master Fund has entered
into an agreement with InvestorCom for solicitation and advisory services in connection with this solicitation, for which InvestorCom
will receive a fee of $[______], together with reimbursement for its reasonable out-of-pocket expenses, and will be indemnified against
certain liabilities and expenses, including certain liabilities under the federal securities laws. InvestorCom will solicit proxies from
individuals, brokers, banks, bank nominees and other institutional holders. LifeSci has requested banks, brokerage houses and other custodians,
nominees and fiduciaries to forward all solicitation materials to the beneficial owners of the shares of Common Stock they hold of record.
LifeSci Master Fund will reimburse these record holders for their reasonable out-of-pocket expenses in so doing. It is anticipated that
InvestorCom will employ approximately [__] persons to solicit stockholders for the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The entire expense of soliciting
proxies is being borne by LifeSci Master Fund. Costs of this solicitation of proxies are currently estimated to be approximately $[_____]
(including, but not limited to, fees for attorneys, solicitors and other advisors, and other costs incidental to the solicitation). LifeSci
estimates that through the date hereof its expenses in connection with this solicitation are approximately $[_____]. To the extent legally
permissible, if LifeSci is successful in its proxy solicitation, LifeSci Master Fund intends to seek reimbursement from the Company for
the expenses it incurs in connection with this solicitation. LifeSci Master Fund does not intend to submit the question of such reimbursement
to a vote of security holders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ADDITIONAL PARTICIPANT INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Participants in the solicitation
are anticipated to be LifeSci Master Fund, LifeSci Special Opportunities, LifeSci Offshore, LifeSci GP, LifeSci Management, Pirate Cove,
Mr. Dobkin and the LifeSci Nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal business address
of each of LifeSci Master Fund, LifeSci Offshore and Pirate Cove is c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand
Cayman KY1-9009, Cayman Islands. The principal business address of each of LifeSci Special Opportunities Fund, LifeSci GP, LifeSci Management
and Mr. Dobkin is 250 West 55th Street New York, New York 10019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal business of
LifeSci Master Fund and Pirate Cove is investing in securities. Each of LifeSci Special Opportunities and LifeSci Offshore is a private
investment partnership that serves as a feeder fund of LifeSci Master Fund. In addition, LifeSci Offshore serves as the parent entity
of Pirate Cove, its wholly owned subsidiary. The principal business of LifeSci GP is serving as the general partner of LifeSci Special
Opportunities and LifeSci Master Fund. The principal business of LifeSci Management is serving as the investment manager of LifeSci Master
Fund. The principal occupation of Mr. Dobkin is serving as managing member of each of LifeSci GP and LifeSci Management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date hereof, LifeSci
Master Fund beneficially owns 96,976 shares of Common Stock, including 1,000 shares of Common Stock beneficially owned directly by Pirate
Cove. LifeSci Special Opportunities, as a feeder fund of LifeSci Master Fund, may be deemed to beneficially own the 96,976 shares of Common
Stock beneficially owned by LifeSci Master Fund. LifeSci Offshore, as a feeder fund of LifeSci Master Fund, may be deemed to beneficially
own the 96,976 shares of Common Stock beneficially owned by LifeSci Master Fund. LifeSci GP, as the general partner of LifeSci Master
Fund, may be deemed to beneficially own the 96,976 shares of Common Stock beneficially owned by LifeSci Master Fund. LifeSci Management,
as the investment manager of LifeSci Master Fund, may be deemed to beneficially own the 96,976 shares of Common Stock beneficially owned
by LifeSci Master Fund. Mr. Dobkin, as managing member of each of LifeSci GP and LifeSci Management, may be deemed to beneficially own
the 96,976 shares of Common Stock beneficially owned by LifeSci Master Fund. For information regarding purchases and sales of securities
of the Company during the past two (2) years by certain of the Participants, see <U>Schedule I</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For information regarding
transactions in the securities of the Company by the Participants during the past two years, please see <U>Schedule I</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of Common Stock
owned directly by LifeSci Master Fund and Pirate Cove were purchased with working capital (which may, at any given time, include margin
loans made by brokerage firms in the ordinary course of business).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Mr. Dobkin, by virtue of his
relationship with LS Capital, where he serves as a managing director, will be entitled to receive certain fees and related compensation
in the event that the Company completes a transaction with any of LS Capital&rsquo;s investment banking clients. Other than as set forth
herein, no Participant has a substantial interest, direct or indirect, by securities holdings or otherwise, in any matter to be acted
on at the Annual Meeting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> Except as set forth in this
Proxy Statement (including the Schedules hereto), (i) during the past ten (10) years, no Participant has been convicted in a criminal
proceeding (excluding traffic violations or similar misdemeanors); (ii) no Participant directly or indirectly beneficially owns any securities
of the Company; (iii) no Participant owns any securities of the Company which are owned of record but not beneficially; (iv) no Participant
has purchased or sold any securities of the Company during the past two (2) years; (v) no part of the purchase price or market value
of the securities of the Company owned by any Participant is represented by funds borrowed or otherwise obtained for the purpose of acquiring
or holding such securities; (vi) no Participant is, or within the past year was, a party to any contract, arrangements or understandings
with any person with respect to any securities of the Company, including, but not limited to, joint ventures, loan or option arrangements,
puts or calls, guarantees against loss or guarantees of profit, division of losses or profits, or the giving or withholding of proxies;
(vii) no associate of any Participant owns beneficially, directly or indirectly, any securities of the Company; (viii) no Participant
owns beneficially, directly or indirectly, any securities of any parent or subsidiary of the Company; (ix) no Participant or any of his,
her or its associates was a party to any transaction, or series of similar transactions, since the beginning of the Company&rsquo;s last
fiscal year, or is a party to any currently proposed transaction, or series of similar transactions, to which the Company or any of its
subsidiaries was or is to be a party, in which the amount involved exceeds $120,000; (x) no Participant or any of his, her or its associates
has any arrangement or understanding with any person with respect to any future employment by the Company or its affiliates, or with
respect to any future transactions to which the Company or any of its affiliates will or may be a party; (xi) no Participant has a substantial
interest, direct or indirect, by securities holdings or otherwise, in any matter to be acted on at the Annual Meeting; (xii) no Participant
holds any positions or offices with the Company; (xiii) no Participant has a family relationship with any director, executive officer,
or person nominated or chosen by the Company to become a director or executive officer; and (xiv) no companies or organizations, with
which any of the Participants has been employed in the past five years, is a parent, subsidiary or other affiliate of the Company. There
are no material proceedings to which any Participant or any of his, her or its associates is a party adverse to the Company or any of
its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries. Except as disclosed herein, with respect
to each of the LifeSci Nominees, (a) none of the events enumerated in Item 401(f)(1)-(8) of Regulation S-K of the Exchange Act (&ldquo;Regulation
S-K&rdquo;) occurred during the past ten years, (b) there are no relationships involving any LifeSci Nominee or any LifeSci Nominee&rsquo;s
associates that would have required disclosure under Item 407(e)(4) of Regulation S- K had such LifeSci Nominee been a director of the
Company, and (c) none of the LifeSci Nominees nor any of their associates has received any fees earned or paid in cash, stock awards,
option awards, non-equity incentive plan compensation, changes in pension value or nonqualified deferred compensation earnings or any
other compensation from the Company during the Company&rsquo;s last completed fiscal year, or was subject to any other compensation arrangement
described in Item 402 of Regulation S-K. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no material proceedings
to which any Participant or any of his, her or its associates is a party adverse to the Company or any of its subsidiaries or has a material
interest adverse to the Company or any of its subsidiaries. With respect to the LifeSci Nominees, none of the events enumerated in Item
401(f)(1)-(8) of Regulation S-K of the Exchange Act occurred during the past ten (10) years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OTHER MATTERS AND ADDITIONAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci is unaware of any
other matters to be considered at the Annual Meeting. However, should other matters, which LifeSci is not aware of at a reasonable time
before this solicitation, be brought before the Annual Meeting, the persons named as proxies on the enclosed <B>BLUE</B> proxy card will
vote on such matters in their discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some banks, brokers and other
nominee record holders may be participating in the practice of &ldquo;householding&rdquo; proxy statements and annual reports. This means
that only one copy of this Proxy Statement may have been sent to multiple stockholders in your household. We will promptly deliver a separate
copy of the document to you if you write to our proxy solicitor, InvestorCom, at the address set forth on the back cover of this Proxy
Statement, or call toll free at (877) 972-0090. If you want to receive separate copies of our proxy materials in the future, or if you
are receiving multiple copies and would like to receive only one copy for your household, you should contact your bank, broker or other
nominee record holder, or you may contact our proxy solicitor at the above address and phone number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information concerning
the Company and the proposals in the Company&rsquo;s proxy statement contained in this Proxy Statement has been taken from, or is based
upon, publicly available documents on file with the SEC and other publicly available information. Although we have no knowledge that would
indicate that statements relating to the Company contained in this Proxy Statement, in reliance upon publicly available information, are
inaccurate or incomplete, to date we have not had access to the books and records of the Company, were not involved in the preparation
of such information and statements and are not in a position to verify such information and statements. All information relating to any
person other than the Participants is given only to the knowledge of LifeSci.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Proxy Statement is dated
________, 2022. You should not assume that the information contained in this Proxy Statement is accurate as of any date other than such
date, and the mailing of this Proxy Statement to stockholders shall not create any implication to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">STOCKHOLDER PROPOSALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Company&rsquo;s
proxy statement, under the rules of the SEC, stockholders wishing to have a proposal included in the Company&rsquo;s proxy statement for
the 2023 Annual Meeting must submit the proposal so that the Corporate Secretary of the Company receives it no later than 120 days prior
to the one-year anniversary of the date of the Company&rsquo;s proxy statement. The SEC rules set forth standards as to what stockholder
proposals are required to be included in a proxy statement. Under the Bylaws, certain procedures must be followed for a stockholder to
nominate persons as directors or to introduce a proposal at an annual meeting of stockholders. Subject to certain exceptions described
in the Bylaws, a stockholder wishing to make a nomination for election to the Board or to have a proposal presented at an annual meeting
of stockholders must submit written notice of such nomination or proposal so that the Corporate Secretary of the Company receives it no
later than the date which is 90 days prior to the one year anniversary of the Company&rsquo;s proxy statement and no earlier than the
date which is 120 days prior to the one year anniversary of the Company&rsquo;s proxy statement. The Bylaws also set forth certain informational
requirements for stockholders&rsquo; nominations of directors and proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> In addition to satisfying
the requirements under the Bylaws with respect to advance notice of any nomination, any stockholder that intends to solicit proxies in
support of director nominees other than the Company&rsquo;s director nominees must provide the requisite written notice to the Company
in accordance with Rule 14a-19 of the Exchange Act. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set forth
above regarding the procedures for submitting stockholder proposals for consideration at the 2023 Annual Meeting is based on information
contained in the Company&rsquo;s proxy statement and the Bylaws. The incorporation of this information in this Proxy Statement should
not be construed as an admission by LifeSci that such procedures are legal, valid or binding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTAIN ADDITIONAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WE HAVE OMITTED FROM THIS
PROXY STATEMENT CERTAIN DISCLOSURE REQUIRED BY APPLICABLE LAW THAT IS EXPECTED TO BE INCLUDED IN THE COMPANY&rsquo;S PROXY STATEMENT RELATING
TO THE ANNUAL MEETING BASED ON OUR RELIANCE ON RULE 14A-5(C) UNDER THE EXCHANGE ACT. THIS DISCLOSURE IS EXPECTED TO INCLUDE, AMONG OTHER
THINGS, CURRENT BIOGRAPHICAL INFORMATION ON THE COMPANY&rsquo;S DIRECTORS AND EXECUTIVE OFFICERS, INFORMATION CONCERNING EXECUTIVE COMPENSATION
AND DIRECTOR COMPENSATION, INFORMATION CONCERNING THE COMMITTEES OF THE BOARD AND OTHER INFORMATION CONCERNING THE BOARD, INFORMATION
CONCERNING CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, INFORMATION ABOUT THE COMPANY&rsquo;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM AND OTHER IMPORTANT INFORMATION. <B>STOCKHOLDERS ARE DIRECTED TO REFER TO THE COMPANY&rsquo;S PROXY STATEMENT FOR THE FOREGOING INFORMATION,
INCLUDING INFORMATION REQUIRED BY ITEM 7 OF SCHEDULE 14A WITH REGARD TO THE COMPANY&rsquo;S NOMINEES. STOCKHOLDERS CAN ACCESS THE COMPANY&rsquo;S
PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS DISCLOSING THIS INFORMATION, WITHOUT COST, ON THE SEC&rsquo;S WEBSITE AT WWW.SEC.GOV</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SEE SCHEDULE II FOR INFORMATION
REGARDING PERSONS WHO BENEFICIALLY OWN MORE THAN 5% OF THE SHARES AND THE OWNERSHIP OF THE SHARES BY THE DIRECTORS AND MANAGEMENT OF THE
COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information concerning
the Company contained in this Proxy Statement and the Schedules attached hereto has been taken from, or is based upon, publicly available
documents on file with the SEC and other publicly available information. Although we have no knowledge that would indicate that statements
relating to the Company contained in this Proxy Statement, in reliance upon publicly available information, are inaccurate or incomplete,
to date we have not had access to the books and records of the Company, were not involved in the preparation of such information and statements
and are not in a position to verify such information and statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Your vote is important. No matter how many shares
of Common Stock you own, please vote to elect the LifeSci Nominees by marking, signing, dating and mailing the enclosed BLUE universal
proxy card promptly.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"><B>LifeSci Special Opportunities Master Fund Ltd.<BR>
<BR>
_________________, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE I</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TRANSACTIONS IN SECURITIES OF <FONT STYLE="text-transform: uppercase">the
COMPANY DURING</FONT> THE PAST TWO YEARS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Nature of Transaction</U></FONT></TD>
    <TD STYLE="width: 35%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Securities Purchased/(Sold)</U></FONT></TD>
    <TD STYLE="width: 33%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Purchase/Sale</U>&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>LIFESCI SPECIAL OPPORTINITIES MASTER FUND
LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,000</FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">05/02/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">05/03/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,990</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">05/04/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,610</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">05/05/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,500</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">05/06/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,900</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">05/09/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,890</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">05/10/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,110</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">05/11/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">60</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">06/14/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">450</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">06/16/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">140</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">06/17/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">06/27/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,112</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">06/29/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">07/05/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">07/28/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,870</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">07/29/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,924</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">08/02/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">513</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">08/22/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,897</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/01/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,113</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/02/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,082</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/06/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,202</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/07/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,191</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/08/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,798</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/09/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">250</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/20/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,071</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/21/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">394</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/22/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,587</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/23/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,991</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/26/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">13</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/29/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">356</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">09/30/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,519</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">10/03/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,090</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">10/11/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">55</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">10/12/2022</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">104</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">10/13/2022</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">94</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">10/14/2022</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase of Common Stock</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">100</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">10/17/2022</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">Disposition of Common Stock<SUP>1</SUP></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">11/18/2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>PIRATE COVE CAPITAL LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Receipt of Common Stock</FONT><SUP>1</SUP></TD>
    <TD STYLE="vertical-align: top; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">11/18/2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1 </SUP>Represents an internal transfer of shares from LifeSci
Special Opportunities Master Fund Ltd. to Pirate Cove Capital Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE II</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>The following table
is reprinted from the Company&rsquo;s preliminary proxy statement filed with the Securities and Exchange Commission on November 18, 2022.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85pt 0pt 0; text-align: justify; text-indent: 0.5in">Based on information
available to us and filings with the SEC, the following table sets forth certain information regarding the beneficial ownership (as defined
by Rule 13d-3 under the Exchange Act) of our outstanding common stock as of the Record Date for (i) each person or group of affiliated
persons known by us to be the beneficial owner of more than 5% of our common stock, if any, (ii) each of our current directors and nominees
for director; (iii) each of our current named executive officers (as defined in Item 402(a)(3) of Regulation S-K under the Exchange Act);
and (iv) all of our current directors, nominees for director, and named executive officers as a group. As of the Record Date, no beneficial
owner owned 5% or more of the shares of common stock then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0.5pt; text-align: justify; text-indent: 35.5pt">Beneficial
ownership and percentage ownership are determined in accordance with the rules of the SEC and include voting or investment power with
respect to shares of stock. This information does not necessarily indicate beneficial ownership for any other purpose. Under these rules,
shares of common stock issuable under stock options or warrants that are exercisable or convertible within 60 days of the Record Date
are deemed outstanding for the purpose of computing the beneficial ownership percentage of the holder thereof, but are not deemed outstanding
for the purpose of computing the beneficial ownership percentage of any other person. Ownership is based upon information provided by
each respective director and officer and public documents filed with the SEC, including Forms 3 and 4, Schedules 13D and 13G and certain
other documents, which information may not be accurate as of the Record Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0.5pt; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0.5pt; text-align: justify; text-indent: 35.5pt">Unless otherwise
indicated and subject to applicable community property laws, to our knowledge, each stockholder named in the following table possesses
sole voting and investment power over their shares of common stock, except for those jointly owned with that person&rsquo;s spouse. Unless
otherwise indicated below, the address of each person listed on the table is c/o Diffusion Pharmaceuticals Inc. 300 East Main Street,
Suite 201, Charlottesville, Virginia 22902.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-align: right; text-indent: -0.5pt"><B>&#9;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 2pt solid; font-size: 10pt; text-align: left"><B>Name and Address of Beneficial Owner</B></TD><TD STYLE="border-bottom: Black 2pt solid; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 2pt solid; font-size: 10pt; text-align: center"><B>Number of&nbsp; <BR>Shares(1)</B></TD><TD STYLE="border-bottom: Black 2pt solid; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 2pt solid; font-size: 10pt; text-align: center"><B>Percentage of <BR>Total Voting <BR>Power(2)</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">Current Directors and Director Nominees</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; font: 10pt Times New Roman, Times, Serif; text-align: left">Robert Adams (3)</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center">3,585</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Robert J. Cobuzzi, Jr., Ph.D. (4)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">7,329</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Eric Francois (5)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3,332</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Mark T. Giles (6)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4,589</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Jane H. Hollingsworth (7)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4,083</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Diana Lanchoney, M.D. (8)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3,332</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Alan Levin (9)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3,487</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">Named Executive Officers (other than Dr. Cobuzzi)</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">William R. Elder (10)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">4,854</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Christopher D. Galloway, M.D. (11)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6,226</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">William K. Hornung (12)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">5,399</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Raven Jaeger (13)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">1,556</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">* </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>All Current Directors, Director Nominees, </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>and Named Executive Officers as a Group</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">(eleven persons) (14)&#9;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">47,772</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">2.3%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85pt 0pt 0; text-indent: -0.5pt"></P>

<!-- Field: Page; Sequence: 41; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85pt 0pt 0; text-indent: -0.5pt">* Indicates less than 1.0%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">1)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Includes shares of common stock held as of the Record Date plus shares of common
stock that may be acquired upon exercise of options, warrants and other rights exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">2)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Based on an estimated 2,039,441 shares of common stock issued and outstanding as
of the Record Date. The percentage ownership and voting power for each person (or all directors and executive officers as a group) is
calculated by assuming (i) the exercise or conversion of all options, warrants and convertible securities exercisable or convertible within
60 days of the Record Date held by such person and (ii) the non-exercise and non-conversion of all outstanding warrants, options and convertible
securities held by all other persons (including our other directors and executive officers).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">3)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of (a) 34 shares held directly by Mr. Adams, (b) 12 shares held jointly
with Mr. Adams&rsquo; wife, (c) 25 shares held for the benefit of Mr. Adams in his 401(k) retirement account, and (d) 3,514 shares of
common stock issuable upon the exercise of options exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">4)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of (a) 1,410 shares held directly by Dr. Cobuzzi and (b) 5,919 shares
of common stock issuable upon the exercise of options exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">5)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of 3,332 shares of common stock issuable upon the exercise of options
exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">6)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of (a) 5 shares held for the benefit of Mr. Giles in his individual retirement
account, (b) 1,070 shares held by MTG Investment Holdings, LLC, and (c) 3,514 shares of common stock issuable upon the exercise of options
exercisable within 60 days of the Record Date. Mr. Giles is the sole member of MTG Investment Holdings, LLC and may be deemed to be the
beneficial owner of such securities. Mr. Giles disclaims beneficial ownership of such securities except to the extent of his pecuniary
interest therein.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">7)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of (a) 886 shares held directly by Ms. Hollingsworth, (b) 183 shares of
common stock issuable upon vesting of restricted stock units expected to vest within 60 days of the Record Date, and (c) 3,014 shares
of common stock issuable upon the exercise of options exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">8)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of 3,332 shares of common stock issuable upon the exercise of options
exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">9)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of (a) 33 shares held by Mr. Levin directly and (b) 3,454 shares of common
stock issuable upon the exercise of options exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">10)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of (a) 400 shares held directly by Mr. Elder and (b) 4,454 shares of common
stock issuable upon the exercise of options exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">11)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of (a) 400 shares held for the benefit of Dr. Galloway in his individual
retirement account, (b) 200 shares held for the benefit of Dr. Galloway&rsquo;s wife in her individual retirement account, and (c) 5,626
shares of common stock issuable upon the exercise of options exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">12)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of 5,399 shares of common stock issuable upon the exercise of options
exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">13)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Consists of 1,556 shares of common stock issuable upon the exercise of options
exercisable within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">14)</FONT></TD><TD STYLE="text-align: justify; padding-right: 0.85pt">Includes (a) 43,114 shares of common stock issuable upon the exercise of options
exercisable within 60 days of the Record Date and (b) 183 shares of common stock issuable upon vesting of restricted stock units expected
to vest within 60 days of the Record Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IMPORTANT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your vote is important. No
matter how many shares of Common Stock you own, please give LifeSci your proxy <B>FOR</B> the election of the LifeSci Nominees and in
accordance with LifeSci&rsquo;s recommendations on the other proposals on the agenda for the Annual Meeting by <B>SIGNING, DATING AND
MAILING</B> the enclosed <B>BLUE</B> universal proxy card TODAY in the envelope provided (no postage is required if mailed in the United
States).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>If any of your shares of
Common Stock are held in the name of a broker, only it can vote such shares of Common Stock and only upon receipt of your specific instructions.
</B>Depending upon your broker, you may be able to vote either by toll-free telephone or by the Internet. Please refer to the enclosed
voting form for instructions on how to vote electronically. You may also vote by signing, dating and returning the enclosed <B>BLUE</B>
voting form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have any questions
or require any additional information concerning this Proxy Statement, please contact InvestorCom at the phone number or address set forth
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">19 Old Kings Highway S. &ndash; Suite 130</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Darien, Connecticut 06820</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Toll Free (877) 972-0090</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Banks and Brokers call collect (203) 972-9300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">info@investor-com.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">4</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: red">PRELIMINARY COPY
SUBJECT TO COMPLETION<BR>
DATED DECEMBER 2, 2022 <BR>
</FONT><BR>
<BR>
DIFFUSION PHARMACEUTICALS INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<BR>
2022 ANNUAL MEETING OF STOCKHOLDERS<BR>
<BR>
THIS PROXY IS SOLICITED ON BEHALF OF LIFESCI SPECIAL OPPORTINITIES MASTER FUND LTD. AND THE OTHER PARTICIPANTS IN ITS SOLICITATION<BR>
<BR>
THE BOARD OF DIRECTORS OF DIFFUSION PHARMACEUTICALS INC.<BR>
IS NOT SOLICITING THIS PROXY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">P R O X Y</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned appoints David
Dobkin and John Grau and each of them, attorneys and agents with full power of substitution to vote all shares of Common Stock, par value
$0.001 per share, of Diffusion Pharmaceuticals Inc. (the &ldquo;Company&rdquo;) which the undersigned would be entitled to vote if personally
present at the 2022 Annual Meeting of Stockholders of the Company scheduled to be held virtually via a live webcast at [_______] on December
30, 2022 at [_:__] a.m. Eastern Time (including any adjournments or postponements thereof and any meeting called in lieu thereof, the
 &ldquo;Annual Meeting&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby revokes
any other proxy or proxies heretofore given to vote or act with respect to the shares of Common Stock of the Company held by the undersigned,
and hereby ratifies and confirms all action the herein named attorneys and proxies, their substitutes, or any of them may lawfully take
by virtue hereof. If properly executed, this Proxy will be voted as directed on the reverse and in the discretion of the herein named
attorneys and proxies or their substitutes with respect to any other matters as may properly come before the Annual Meeting that are unknown
LifeSci Special Opportunities Master Fund Ltd. (together with the other participants in its solicitation &ldquo;LifeSci&rdquo;) a reasonable
time before this solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS PROXY WILL BE VOTED
AS DIRECTED. IF NO DIRECTION IS INDICATED WITH RESPECT TO THE PROPOSALS ON THE REVERSE, THIS PROXY WILL BE VOTED &ldquo;FOR&rdquo; THE
SIX (6) LIFESCI NOMINEES IN PROPOSAL NO. 1, &ldquo;FOR&rdquo; PROPOSAL NO. 2 AND &ldquo;AGAINST&rdquo; PROPOSAL NO. 3. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Proxy will be valid until
the completion of the Annual Meeting. This Proxy will only be valid in connection with LifeSci&rsquo;s solicitation of proxies for the
Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">IMPORTANT: PLEASE SIGN, DATE AND MAIL THIS
PROXY CARD PROMPTLY!<BR>
<BR>
CONTINUED AND TO BE SIGNED ON REVERSE SIDE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>[X] Please mark vote as in this example&#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>LIFESCI
</B></FONT><B>STRONGLY RECOMMENDS THAT STOCKHOLDERS VOTE <FONT STYLE="text-transform: uppercase">&ldquo;for&rdquo; </FONT>THE SIX <FONT STYLE="text-transform: uppercase">LIFESCI
</FONT>NOMINEES, AND NOT TO VOTE &ldquo;FOR&rdquo; ANY OF THE REMAINING COMPANY NOMINEES LISTED BELOW IN PROPOSAL NO. 1.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>YOU MAY SUBMIT VOTES &ldquo;FOR&rdquo; UP TO
SIX NOMINEES IN TOTAL. YOU ARE PERMITTED TO VOTE FOR LESS THAN SIX NOMINEES. IMPORTANTLY, IF YOU MARK MORE THAN SIX &ldquo;FOR&rdquo;
BOXES WITH RESPECT TO THE ELECTION OF DIRECTORS, ALL OF YOUR VOTES FOR THE ELECTION OF DIRECTORS WILL BE DEEMED INVALID. IF YOU MARK FEWER
THAN SIX &ldquo;FOR&rdquo; BOXES WITH RESPECT TO THE ELECTION OF DIRECTORS, THIS PROXY CARD, WHEN DULY EXECUTED, WILL BE VOTED ONLY &ldquo;FOR&rdquo;
THOSE NOMINEES YOU HAVE SO MARKED.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Election of Directors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 52%; border: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>LIFESCI Nominees</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>FOR</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>WITHHOLD</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Jill Davidson</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Tenzin Khangsar</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Jeffrey Kimbell</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Jessica M. Lockett</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Jeffrey Max </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>John Ziegler</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 52%; border: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>COMPANY Nominees OPPOSED BY LIFESCI</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>FOR</B></FONT></TD>
    <TD STYLE="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>WITHHOLD</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Robert Adams</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Robert J. Cobuzzi</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Mark T. Giles</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Jane H. Hollingsworth</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Diana Lanchoney</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 17.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Alan Levin</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&nbsp;&#9744;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>LIFESCI
</B></FONT><B>MAKES NO RECOMMENDATION WITH RESPECT TO PROPOSAL NO. 2.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The Company&rsquo;s proposal to ratify the selection of KPMG LLP as the Company&rsquo;s independent registered
public accounting firm for the year ending December 31, 2022.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 8%; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 26%; text-align: center"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">FOR</FONT></TD>
    <TD STYLE="width: 8%; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">AGAINST</FONT></TD>
    <TD STYLE="width: 8%; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">ABSTAIN</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; text-align: center; font-size: 10pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>LIFESCI
</B></FONT><B>MAKES NO RECOMMENDATION WITH RESPECT TO PROPOSAL NO. 3.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">The Company&rsquo;s proposal to approve, on an advisory basis, the compensation of the Company&rsquo;s
named executive officers during the year ended December 31, 2021.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="width: 8%; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 26%; text-align: center"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">FOR</FONT></TD>
    <TD STYLE="width: 8%; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">AGAINST</FONT></TD>
    <TD STYLE="width: 8%; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">ABSTAIN</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DATED: ____________________________<BR>
<BR>
____________________________________<BR>
(Signature)<BR>
<BR>
____________________________________<BR>
(Signature, if held jointly)<BR>
<BR>
____________________________________<BR>
(Title)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEN SHARES ARE HELD JOINTLY, JOINT OWNERS SHOULD
EACH SIGN. EXECUTORS, ADMINISTRATORS, TRUSTEES, ETC., SHOULD INDICATE THE CAPACITY IN WHICH SIGNING. PLEASE SIGN EXACTLY AS NAME APPEARS
ON THIS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !( /T# 2(  A$! Q$!_\0
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-!E5K5D)...M%% C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !( /T# 2(  A$! Q$!_\0
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M7.NYJS(C2C%W1Y)XG^$-X+J2Z\/O')$[;A;2-M*?1JQX_AMXTU.6..^7;&G
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MX X&?<U5DO?'$.D?V^SV+*L7G/IHB(8)U/SYZXHY4!V'V"U_YXC\S1]@M?\
MGB/S-<]+XJDGD\-36(7[-K$N'WCD#:3@?B*O^+-4N=&\-7FH6FSSXE&S>,C)
M(']:.5 :7V"U_P">(_,T?8+7_GB/S-<GJ.J^*_#EC'JU[+9:E8KM-PD,1C=%
M/<<G-3:WKNIGQ!INGZ5?6=I#=VCSM-<IN'!& .1ZT<J Z;[!:_\ /$?F:/L%
MK_SQ'YFN9\0:SK&@^$UNQ>VEU>-<)&)DCQ'ACCIG^M.TS6]7M_%<>A:I<VEX
M+BV,\<ULA4I@\AADT<J Z3[!:_\ /$?F:/L%K_SQ'YFL7Q'KEYI>M:!9VXC,
M>HW;13;ASM"YXK.N/&-SI_Q!DTB]C1=+81QQ3@?<E9<@,??I1RH#J_L%K_SQ
M'YFC[!:_\\1^9K L]4U;5KS7K*TG@MY+*X6."22,L ",G(R,U1T6]\5:EK&H
MV<FIV*IIUPL4F+8YD! .1SQUHY4!UOV"U_YXC\S1]@M?^>(_,UR:ZOKVHZ[J
MEM:ZMIUC!93K$J3Q;F8;0?[PK4GU>]M_%FEZ03&\5S;/)*X'5E]/:GRH#8^P
M6O\ SQ'YFC[!:_\ /$?F:R?%FLW6BV-K/:A2TMY%"VX=F8 UI:O=266D7EU%
MCS(87=<],@9I<J D^P6O_/$?F:/L%K_SQ'YFN5/C"\C\*Z-<I;I<:MJX"019
MVIN[D^PK2TVW\3Q7\;ZEJMA- P/F010%64XXP<^M'*@-C[!:_P#/$?F:/L%K
M_P \1^9KDVUC7M0\0ZM96FJZ?806,J1H+B+<SY&<_>%)XP\6ZGX9O]'6.&.Y
MMY5=[W8/F*KM!9?SS19=@.M^P6O_ #Q'YFC[!:_\\1^9K%/B&2;Q9IMC;21O
M87MD]P'[G&,8/IS6?'JOB+Q/>78T.>VT_3[64PK<31F1YG'7 R,+19=@.J^P
M6O\ SQ'YFG);0QYV1XSUP:Y3Q)K.O:'8Z+;BZL_MM[=BWFN&C/E@$$YQFMO1
M3J*I-_:6IVE\21L-M'L"^N>33LNP'%^+#;ZI>$Z5H>I6WB*.91!<+ 8PRAAE
MF;H5QZUH:KX>36?']E_:M@;FT33R'=A\F_([T44##2-$BT#Q[J,EAIKPV(L%
M92B_*S@G(SZUD1^#M5UOPOJ6HSWEW;75_,UT+$QKC<I_=@DC/0"BB@#2U:"?
MQ+I_A-KNSF.;C-V@!4H=A!SCIS3]'TI_#^H>)=(M[61K.X@^T6TA&<DJ04W=
M2<],T44 4_!-OX?L5TU)-"O(M6 VM.UHX4/S_%TJUIOA*PU7Q=XAN-9TL2JT
MZ>2\J\$;1THHH KVGA.2X\-^)]%M[5K59+QFM$8%0V.1CVXZU:G\6WUUX>?2
MH]"O_P"V9(# T)A(C4D;2V_ICO110!#?Z;+X<L_"*&&XN8]+D/GF",R$94YX
M'N:T/$NI?\)#X*U-=/LKSS% _=RV[(S8(/ /6BBF!5UG5KWQ-H@T'1M*O0]R
MJQS7%S 8HX4XW')ZGZ57\4Z5I\/B;14U'3+B^T^VL'C/E0F3:V1C.***0#_$
M5I:ZCX!2UT32[J&W6\C7[.T+(P&X9.#SCWJWINA#PYX\0V-K)]AU&T(D9LN4
MD7_:/(!!HHI@6?%]I<W'B+PK+!!))'!?,TK*,A!MZD]A4=SX?76]:\2VEU$Z
M0W*6_E2XQAPG!4^H-%%("'X=6^JVTNM?VQ"\=Q]H52Y'$FT$;AZ\8J_X8MYH
M?$?B626%DCEO%*,PX;Y!THHIB.:ELM%C\5:W-KVAW=T\ERK6\L=JSC 4=Q6O
MK-V+/Q=HFK?8KM[)+.1?W,#,R9Z CM110,/%FH?VSX:M;RSL[PK!?Q.\;V[+
M)A6!)VGFM&YUR'7M%U2VM+.^246SX$]LT>[CMGK110!SYTK5HO"OA;4K.RDF
MN]'^>2TZ.Z,,,![U'>N-:\9Z-J&EZ;JT%Q]H4WYFC=$6,# !!..M%%(".ZL=
M&7Q9KLOB#0[N\$LJ&WDCM6D 7'/(]ZWM1M_MWBOP]-%:R&R%K.KADQM4A0 P
M[444 8N@Z!J6B?$6.QDCDDTB&UF-I,>BHQ'R$^QS5O1]3F\$O>:7JNG7;V9N
M'EM+JVB,BNK'.TX[T44 ,\>%-:TS0+N33+R2S%\))X3"?,$>TYRO6MOPU/H=
6I%<)H^CWMHI8&56M60DXXZT44"/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" #! 9H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#QK<?[Q_.C
M<W]X_G6MH?AF^\0;S9&(;)HH3YC8^:0D+^'%7X? 6K/,T<\MK:;&G61KB3:(
M_*QN)XZ?,,>M '-;F_O'\Z-S?WC^==*W@'6C,8H1;W&7B6)HI=RS"3.UE/<?
M*<^F*A?P;??VM9Z=;WEA=M>$B.:WN T:[?O;C_#CW% &!N;^\?SHWG^\?SKI
M;?P->S#4/-U'3[5]-8K<1SS%64 X#=.A)&#[TZ/P!JC32I+=6-LJ2+%')//M
M6:1E#!$XY."* .8W-_>/YT;C_>/YUT:^ M<,5M(\4<:W+S1C<WW'B!+*WH>#
MCUKFZ %WG^\?SHWG^\?SI** %WG^\?SK4T@DV>J<G_CT]?\ :6LJM31_^//5
M?^O0_P#H2T 9FYO[Q_.C<W]X_G5C3K&;4]1M["WVB6YD6--QP,DX&:Z3_A7.
MI^< M_IS6_ER.;E9B8UV$!P>,Y!([4 <GN;^\?SHW-_>/YUU@^'6IK+<K<7M
MA;I;^7^]DE;:XD7<I7 )Z#O5(>#;_P#LQKYKJQ12KO#%).%DN$4X+HIZC@X]
M: ,#<W]X_G1N/]X_G6NWAB_76I=)+0_:(H3,QW?+M";^OKBKS^ =:CN5MY%A
M5G2!T8OPXF.%(./7KZ4 <UN/]X_G1N;^\?SKH)O!6I6^GR7<]Q91,JO(EN\X
M662-20753U&0?<TB^"M7:/2)-L075VVP9?[IZC?_ '<CD>U &!N;^\?SK6MR
M?^$6O3D_\?47\FK+EB:&5XFQN1BIQZ@UIV__ "*M[_U\Q?R:@#*W-_>/YT;C
M_>/YTE:&B:-<:[J(L;>2&)RC2%YFVJJJ,DD_2@"AN/\ >/YT;C_>/YUT5]X&
MU:QMY+@&"YA41,CV[%Q(LF=K+QG'RFFR>"-8C&KG$+#1^+C#_>.,G;ZX')H
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MW_@._P#A7UIYC?WC1O;^\: /DO\ L'6/^@3??^ [_P"%']@ZQ_T";[_P'?\
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M&*(-%U4>&;R,Z7>!C<QD#R&SC#>U?4/F-_>-*';:>>] 'R5_8.L?] F^_P#
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M=>[?V#HW_0*M?^_0I/[ T;_H%6O_ 'Z%'U)]P_UHA_S[?WGA6Y?[P_.C<O\
M>'YU[K_8.C?] NU_[]"E_L'1O^@7:_\ ?H4?4GW#_6B'_/M_>>$[E_O#\Z-R
M_P!X?G7NW]@Z-_T"[7_OT*7^P-&VD_V7:]?^>0H^I/N'^M$/^?;^\\(W+_>'
MYT;E_O#\Z]V_L'1O^@5:_P#?H4?V#HW_ $"[7_OT*/J3[A_K1#_GV_O/"=R_
MWA^=&Y?[P_.O=O[!T;_H%VO_ 'Z%']@Z-_T"[7_OT*/J3[A_K1#_ )]O[SPG
M<O\ >'YT;E_O#\Z]V_L'1_\ H%VO_?H4?V#H_P#T"K7_ +]"CZD^X?ZT4_\
MGV_O/"=R_P!X?G1N7^\/SKW;^P=&_P"@7:_]^A1_8.C?] JU_P"_0H^I/N'^
MM$/^?;^\\)W+_>'YT;E_O#\Z]W'A_1BI/]EVO'_3(4G]@:-_T"K7_OT*/J3[
MA_K1#_GV_O/"=R_WA^=&Y?[P_.O=O[!T;_H%6O\ WZ%']@Z-_P! JU_[]"CZ
MD^X?ZT0_Y]O[SPG<O]X?G1N7^\/SKW7^P-&_Z!5K_P!^A1_8&C?] JU_[]"C
MZD^X?ZT0_P"?;^\\*W+_ 'A^=&Y?[P_.O=O[!T;_ *!5K_WZ%']@Z-_T"[7_
M +]"CZD^X?ZT0_Y]O[SPG<O]X?G2@@]#GZ5[I_8.C?\ 0*M?^_0KG-;\$1:K
MXAM1! EII\<69VC4 N<_='O[U,L')+1W-*/$=&I.THV1SWP[TG4[C5UU"VD:
M"TB.V5\<2_[(']:]4IEG:P6<$=M;1K%#&-JH!P!3Z[Z5-4X\I\IF&,>,KNHU
M;M_P0HHHK4X HHHH **** "BBB@!1U%5ZL#J*KT 6#U/UI*>6&3\HZTFX?W1
M0 VBG;A_=%&X?W10 VBG;A_=%&X?W10 VBG;A_=%&X?W10 VBG;A_=%&X?W1
M0 VG+T;Z4;A_<%*&X/RCI0 RBG;A_=%&X?W10 VBG;A_=%&X?W10 VBG;A_=
M%&X?W10 VBG;A_=%&X?W10 VG#[A^M&X?W12[OE/RCK0 RBG;A_<%&X?W10
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M]]"C_A:6G?\ 0.N?^^A67UBEW._^R<=_S[9V]%<1_P +2T[_ *!US_WT*/\
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M% !1110 4444 .3[XIM.3[XIM !1110 4444 %%%% !1110 HZBJ]6!U%5Z
M,;Q/I%SJ^H:<D,5N\<8F+M=0^9&N0,<9'/I6=+'X@TJ>'3].^V2P6\7EB1E!
M5QL)W?\ ?6!US79-U/7K1F@#E"WB"!Q%++?R6X*GS8D4RER@(7TV[LU'.WBA
M$A=9+@-*\I/R!BCAL(N!_#MS_C77T9H XJ[/B*[N)XY([Y+<$,P08VE9%QMQ
MV*YX[BM#37UA;^!+E+N.+/R)'&HB*DMN+^AZ5TN3ZFDH Y5[+9K]RUUHMS>W
MDET);6\0X1(QC WY^7;SD=ZBM9O$UU=M%(U[!;R2(3(R ,G+;@#T ^[TKL,\
M8[49- '("Y\4>0?DNC>B$>2GEKY3#'S%S_>S_2K>C_VY/>VYO)[D6BB1LLFT
MN?EP&R,XSNQTKI,FC- "5PWQ3(&DV.3C]^?_ $&NYIDMM;W*;;B".91R!(H8
M#\ZBI#GBXG5A*_U>O&K:]CY]W#U%&X>M>]_V7IW_ $#[;_OTM']EZ=_T#[;_
M +]#_"N#ZD^Y]5_K1#_GW^)X)N'K1N'K7O?]EZ=_T#[;_OT*/[+T[_H'VW_?
MI:/J3[C_ -:(_P#/O\3P3</44;AZBO>_[+T[_H'VW_?I:/[+T[_H'VW_ 'Z6
MCZD^X?ZT0_Y]_B>";AZBC</45[W_ &7IW_0/MO\ OTM']EZ=_P! ^V_[]+1]
M2?</]:(?\^_Q/!-P]11N'K7O?]EZ=_T#[;_OTM+_ &7IV#_Q+[;_ +]"CZD^
MX?ZT1_Y]_B>![AZBC</45[W_ &7IW_0/MO\ OTM']EZ=_P! ^V_[]+1]2?</
M]:(_\^_Q/!-P]:-P]:][_LO3O^@?;?\ ?I:/[+T[_H'VW_?I:/J3[A_K1'_G
MW^)X)N'J*-P]17O?]EZ=_P! ^V_[]+1_9>G?] ^V_P"_2T?4GW#_ %HC_P ^
M_P 3P3</449KWO\ LO3O^?"V_P"_2US.G^"(6\37FJWT2>0)B;:W X/^T1_2
MI>#DFK,UI\24I*3E&UEIYC/AUHFHZ=9RWEW(\4%R 8[4_P#H1]#79THZ&DKT
M804(\J/C<5B)8BM*K+=A1115G.%%%% !1110 4444 .3[XIM.3[XIM !1110
M 4444 %%%% !1110 HZBJ]6!U%5Z +!ZGZTE/.S)Z]:3]WZM^5 #:*=^[]6_
M*C]WZM^5 #:*=^[]6_*C]WZM^5 #:*=^[]6_*C]WZM^5 #:*=^[]6_*C]WZM
M^5 #:<.A^E'[OU;\J<-F#C/2@".BG?N_5ORH_=^K?E0 VBG?N_5ORH_=^K?E
M0 VBG?N_5ORH_=^K?E0 VBG?N_5ORH_=^K?E0 VE_A/UI?W?JWY4N$V'D]:
M&44[]WZM^5'[OU;\J &T4[]WZM^5'[OU;\J &T4[]WZM^5'[OU;\J &T4[]W
MZM^5'[OU:@!!T-)3QLP>32?N_5J &T4[]WZM^5'[OU;\J &T4[]WZM^5'[OU
M;\J &T4[]WZM^5'[OU;\J &T4[]WZM^5'[OU;\J !/OBFU(FS<,9IOR?[5 #
M:*=^[]6_*C]WZM^5 #:*=^[]6_*C]WZM^5 #:*=^[]6_*C]WZM^5 #:*=^[]
M6_*C]WZM^5 "#J*KU:&S/>JWR^] $YZGZTE4]2U>PTDQ_;IS$92=@"%BV.O
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M^- %ZBL_^U9/^@1J7_?I?\:/[5D_Z!&I?]^E_P : -"BL_\ M63_ *!&I?\
M?I?\:/[5D_Z!&I?]^E_QH T**S_[5D_Z!&I?]^E_QH_M63_H$:E_WZ7_ !H
MT**S_P"U9/\ H$:E_P!^E_QH_M63_H$:E_WZ7_&@#2'W&IM41JT@5A_9&I<_
M],E_QIO]JR?] C4O^_2_XT :%%9_]JR?] C4O^_2_P"-']JR?] C4O\ OTO^
M- &A16?_ &K)_P! C4O^_2_XT?VK)_T"-2_[]+_C0!H45G_VK)_T"-2_[]+_
M (T?VK)_T"-2_P"_2_XT :%%9_\ :LG_ $"-2_[]+_C1_:LG_0(U+_OTO^-
M&DGWQ3:H+JSA@?[(U+_OTO\ C2?VK)_T"-2_[]+_ (T :%%9_P#:LG_0(U+_
M +]+_C1_:LG_ $"-2_[]+_C0!H45G_VK)_T"-2_[]+_C1_:LG_0(U+_OTO\
MC0!H45G_ -JR?] C4O\ OTO^-']JR?\ 0(U+_OTO^- &A16?_:LG_0(U+_OT
MO^-']JR?] C4O^_2_P"- &B.HJN*K-J[HI9M(U$*HR3Y2]/SJ>WGCN+:*9-^
MV1 PRO.",T :=%9O]MC_ *!NH_\ @,:/[;'_ $#=1_\  8T :5%9O]MC_H&Z
MC_X#&C^VQ_T#=1_\!C0!I45F_P!MC_H&ZC_X#&C^VQ_T#=1_\!C0!I45F_VV
M/^@;J/\ X#&C^VQ_T#=1_P# 8T :5%9O]MC_ *!NH_\ @,:/[;'_ $#=1_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I*** "EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3HHHH **** $/0_2E'2BB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" #_ 9T# 2(  A$! Q$!_\0
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M0-D<GI1]8F+^Q<)U1WDGQ$C>>*7[./W6[;\[<Y&/[M/_ .%D+Q_HP_[^-_\
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M-F/F,MLPDVA%<,""P"L<GCC/Y>]4-EM_SVD_[]#_ .*HV6W_ #VD_P"_0_\
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M[H?_ !5*Z[$1A.]^=_<1%RP4'@ 8XIO?BK!^SRN/WT@[<1#_ .*J;[-:!?\
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M-HW&588(/<5A?\(3H/;2[<#_ '3_ (UT!.*;YB?WA2:3W-(5:D/@DUZ,P?\
MA"M!_P"@9!_WR:/^$*T'_H&0?]\FM[S4_O"CS4_O"ER1[%_6:_\ ._O9@_\
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MM[S$_O"CS$_O"CDCV#ZS7_G?WLYZ;P?H$*!FTN @L%X7U./7WI__  A6@_\
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M:22HJ%6UUVV'WFH_;D(FMHPP+&-T)!3/)&.AYYY]34MQK=S<VDEJR(L<B%2
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MNC2R7CW-TQD=CDDT 0Z7IDMS,;N[8O(YR6:NBC15 51@"E5%A0 8%.&#Z9H
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MSVZMYK(<[<XPN?7@G':N2LPA\[(B,P0>4)CA2<C/7C.*T!X0U\=--;_OM?\
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M$ 08?)89==O(8YP#GIGGK4__  BNL[=O]CS;<YV_:1C/TI/^$3UC_H"R?^!
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M_P"?;^XZ[RU]*/+7TKD/^%DZ'_?F_P"_)H_X63H?]^?_ +\FCVL.X?V?BO\
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M<OWP*"68\?G3E&!B@0O?CI2/V'J:4G;UIJ@L=QX]!0,?2T44 %%%% !1110
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M3DOY)IO,F@9P4D1AD@D.2>OMGBG_ -J2D1H]KF&-=JQ@D<94CGVVC\S75?\
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" #\ 9H# 2(  A$! Q$!_\0
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MQ#^R<3Y?>>O45XAK'Q?\3Z=%$\4>GL78@[H&]O\ :K)_X7IXM_YX:9_WX?\
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MMRLJL7 Q]Y,=ZRIBK3R-&6*%R5+=2,]_>O0O^$%T7TN/^_QH_P"$%T7TN/\
MO\:T6)IJ3EJ9O#U'%1T/.Z*]%_X071?2X_[_ !I/^$%T7TN/^_QK3ZY3\R?J
ME0\[IPZ"O0_^$%T7TN/^_P :/^$&T;TN/^_QI?7*?F'U29T=%%%>4>F%%%%
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MV8'7/K2Y']*X?_A9>F?\^UU_WP/\:5/B3IC-@6]UD_[ _P :7M8=P_LW%_\
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MG! ]JY0_#'32?^/BY_[Z7_"N6M2E-W1]!E684<+2E&;U;[7/.OLL_P#SS_\
M'E_QH^RS_P#//_Q]?\:]$_X5CIO_ #WN?^^E_P */^%8Z;_SWN?^^E_PK'ZO
M,]7^V\-W?W?\$\[^RS_\\_\ Q]?\:/LL_P#SS_\ 'E_QKT3_ (5CIO\ SWN?
M^^E_PH_X5CIO_/>Y_P"^E_PH^KS'_;>'[O[O^">=_99_^>?_ (\O^-'V6?\
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M %%%% !1110 4444 %%%% "-TIA;)Q3SR*8K;J '>U'>CWH- "G'>BFL:=0
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M$X+<QL< ^GUH EQQRW'I3QVI@8-@CFI* $HIK$;OFSC%*N=HS0 *".M.HHH
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M&) ^7^(_0"H(--M9EG?[7MBBF95<+EG4%0#C(_O9HM,:JX;71Z%?^T9?6?\
M\"7_ ,:/[1E_O3?^!+_XU8M-,@EMKSSIT6=7:.WR^ [("6..XQ@58;PXJ@LU
M[M7RV<;H^3@XR "<KWSZ$4K3&ZN$B[/]3/\ [1E]9_\ P)?_ !H_M&7UG_\
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MXK"I:*_R,/[;>?\ /W/_ -_31]MO/^?N?_OZ?\:TWT&%'4-?;0[!%_=C));
M;K]PYR#Z9XK%_G4M26YT4I4*OPI?<3_;;S_G[G_[^G_&C[;>?\_<_P#W]/\
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M\\-/_6CV,^P?VGAOYU]YR>*DFGFN&5II&D*C +'H/05U'_""ZY_SPT_]:/\
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MLIIY^84F%'\(- "*54''6G!@:3:,_=IIX(["@"6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK#(XIU% $8(48;K1O ['\J>
M0#VHH 9O'8&EW_[)I]% $>YAU4T#YSDC&*DHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<html>
<head>
<title></title>
</head>
<body bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif; DISPLAY: inline">

<P STYLE="margin: 0pt 0; text-align: right; text-indent: 0pt"></P>

<P STYLE="margin: 0pt 0; text-indent: 0pt">&nbsp;</p>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt times new roman, serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; width: 50%; border-bottom: black 1px solid; text-indent: 0pt"><FONT STYLE="font-family: arial, serif; font-size: 16pt">O&#160;&#160; L&#160;&#160; S&#160;&#160; H&#160;&#160; A&#160;&#160; N</FONT></TD>
    <TD STYLE="text-align: right; width: 50%; border-bottom: black 1px solid; padding: 0; vertical-align: bottom">
<font style="FONT-SIZE: 7pt; FONT-FAMILY: arial, sans-serif; DISPLAY: inline">1325 AVENUE OF THE AMERICAS <font style="FONT-SIZE: 7pt; FONT-FAMILY: arial, sans-serif; DISPLAY: inline">&#9679;</font>&#160;NEW YORK, NEW YORK 10019</font>
<BR>
<font style="FONT-SIZE: 7pt; FONT-FAMILY: arial, sans-serif; DISPLAY: inline">TELEPHONE: 212.451.2300&#160;<font style="FONT-SIZE: 7pt; FONT-FAMILY: arial, sans-serif; DISPLAY: inline">&#9679;</font> <font style="FONT-SIZE: 7pt; FONT-FAMILY: arial, sans-serif">FACSIMILE</font>: 212.451.2222</font>
</TD></TR>
</TABLE>
<P STYLE="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; margin: 0pt 0; font: 7pt Arial, serif; text-align: right">EMAIL:&#160; AFREEDMAN@OLSHANLAW.COM</P>


<P STYLE="text-indent: 0pt; margin: 0pt 0; font: 7pt Arial, serif; text-align: right">DIRECT DIAL:&#160; 212.451.2250</P>

<P STYLE="text-indent: 0pt; margin: 0pt 0; font: 7pt Arial, serif; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">December 2, 2022</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><U>VIA EDGAR, FACSIMILE AND ELECTRONIC MAIL</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Christina Chalk<BR>
Michael Killoy<BR>
Division of Corporation Finance<BR>
Office of Mergers &amp; Acquisitions<BR>
United States Securities and Exchange Commission<BR>
Mail Stop 3628<BR>
100 F Street, N.E.<BR>
Washington, D.C. 20549</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">Re:</TD><TD STYLE="text-align: justify">Diffusion Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)<BR>
Preliminary Proxy Statement on Schedule 14A (the &ldquo;Proxy Statement&rdquo;) filed by LifeSci Special Opportunities Master Fund Ltd.,
et al. (collectively, &ldquo;LifeSci&rdquo;)<BR>
Filed November 22, 2022<BR>
File No. 001-37942</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Dear Ms. Chalk and Mr. Killoy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">We acknowledge receipt
of the comment letter of the Staff (the &ldquo;Staff&rdquo;) of the U.S. Securities and Exchange Commission, dated November 30, 2022 (the
 &ldquo;Staff Letter&rdquo;), with regard to the above-referenced Proxy Statement filed by LifeSci. We have reviewed the Staff Letter with
LifeSci and provide the following responses on its behalf. For ease of reference, the comments in the Staff Letter are reproduced in italicized
form below. Terms that are not otherwise defined have the meanings ascribed to them in the Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><U>Preliminary Proxy Statement on Schedule
14A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><U>Letter to Stockholders, page ii</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">Since shareholders may vote for the nominees of either soliciting party on either proxy card, revise to
explain what you mean by the following statement: &ldquo;We believe that voting on the BLUE universal proxy card provides the best opportunity
for stockholders to elect all of LifeSci&rsquo;s nominees and achieve the best Board composition overall.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">LifeSci acknowledges the
Staff&rsquo;s comment and has revised the Proxy Statement as follows to explain why it believes that stockholders voting on the Blue
universal proxy card provides the best opportunity for stockholders to elect all of LifeSci&rsquo;s nominees:&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt times new roman, serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; border-top: black 1px solid; text-indent: 0pt"><FONT STYLE="font-family: Arial, serif; font-size: 7pt">O L S H A N&#160;&#160; F R O M E&#160;&#160; W O L O S K Y&#160;&#160; L L P</FONT></TD>
    <TD STYLE="text-align: right; border-top: black 1px solid; text-indent: 0pt"><FONT STYLE="font-family: Arial, serif; font-size: 7pt">WWW.OLSHANLAW.COM</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">December 2, 2022</P><P STYLE="margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 12pt; text-align: justify">&ldquo;We believe that voting on the BLUE
universal proxy card provides the best opportunity for stockholders to elect all of LifeSci&rsquo;s nominees and achieve the best Board
composition overall since, according to the Company, any stockholder voting on the white proxy card that does not specify how to vote
with respect to any nominee will be voted by the proxies &ldquo;for&rdquo; the Board&rsquo;s six nominees for director.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Please see pages ii, <FONT>2</FONT>
and <FONT>28</FONT> of the Proxy Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><U>We Believe Our Nominees are the Right Individuals
to Help Maximize Value for Diffusion Stockholders, page 16</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">There appear to be words missing the first sentence of this section on page 16. Please revise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">LifeSci acknowledges the
Staff&rsquo;s comment and has revised the proxy statement accordingly. Please see page <FONT>16</FONT>
of the Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><U>Stockholder Proposals, page 33</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Include the disclosure required by Rule 14a-5(e)(4) regarding the deadline to provide notice of solicitation
of proxies pursuant to Rule 14a-19 for Diffusion&rsquo;s next annual meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">LifeSci acknowledges the
Staff&rsquo;s comment and has revised the proxy statement accordingly. Please see page <FONT>33</FONT>
of the Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><U>General</U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Each statement or assertion of opinion or belief must be clearly characterized as such, and a reasonable
factual basis must exist for such opinion or belief. Support for any such opinions or beliefs should be self-evident, disclosed in the
soliciting materials or otherwise provided to the staff on a supplemental basis with a view toward disclosure. Some examples of opinions
presented as fact that should be recharacterized and/or supported include the following:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal">&#183;</FONT></TD><TD STYLE="text-align: justify">&#8220;Although Diffusion has spent over a decade attempting to develop its lead asset&#8230;.it has yet
to accomplish any sort of meaningful operational milestones other than the seemingly wasteful spending of immense cash resources&#8230;.&#8220;
(pg. 10)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">LifeSci acknowledges the Staff&rsquo;s
comment and has revised the Proxy Statement to clearly indicate that this is a statement of opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, LifeSci respectfully
refers the Staff to the disclosure in the paragraphs immediately following this statement as well as further down in the Reasons for the
Solicitation Section, which LifeSci believes appropriately support this statement. Specifically, LifeSci discusses the Company&rsquo;s
inability to produce a single clinical read-out showing any statistical efficacy for its lead asset, Trans Sodium Crocetinate (TSC), or
to show any clinical benefit for TSC, as discussed in more detail on pages <FONT>10</FONT> through <FONT>14</FONT>
of the Proxy Statement. Instead, in every instance, the Company has either prematurely terminated its clinical trial for TSC, or failed
to meet both the primary and secondary clinical end points previously investigated, but nonetheless continues to spend time and money
attempting develop alternative uses for TSC, despite TSC having been Phase 3 ready for certain indications for nearly seven years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">December 2, 2022</P><P STYLE="margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal">&#183;</FONT></TD><TD STYLE="text-align: justify">&#8220;We believe that the Company&#8217;s operational efforts to develop TSC have failed to accomplish
anything other than a catastrophic erosion of Diffusion&#8217;s cash balances and stockholder value.&#8221; (pg. 15)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">LifeSci acknowledges the Staff&rsquo;s
comment and respectfully refers the Staff to the disclosure on pages 10 through 14 of the Proxy Statement, which provide a chronological
overview of the Company&rsquo;s expensive and unsuccessful efforts to develop new and alternative uses for TSC. Meanwhile, as discussed
on page 14 of the Proxy Statement, the Company was allocating resources to studies that were not even intended to progress the development
of TSC and were not &ldquo;designed or powered to evaluate TSC&rsquo;s efficacy as a treatment,&rdquo; but rather, were &ldquo;designed
as a safety and tolerability study only,&rdquo; which served to further erode the Company&rsquo;s cash balance without even the chance
of generating any value for the Company or its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
LifeSci has revised the Proxy Statement in an effort to address any concerns the Staff may have with use of the phrases &ldquo;accomplish
anything&rdquo; and/or &ldquo;catastrophic&rdquo;. Accordingly, the statement now reads as follows: &ldquo;We believe that the Company
has failed to make any meaningful operational progress to further develop TSC and instead the Company has continuously eroded its cash
balances and stockholder value with, what appear to us as, ill-conceived efforts to find alternative uses for TSC.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal">&#183;</FONT></TD><TD STYLE="text-align: justify">&#8220;It is clear to Us that the Company Has Failed to Generate any Meaningful Value from TSC Since Going
Public and Cannot Be Trusted to Lead the Company Going Forward.&#8221; (pg. 15)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">LifeSci acknowledges the Staff&rsquo;s
comment and has revised the Proxy Statement as follows to clearly indicate that this is a statement of opinion: &ldquo;It Appears to us
That the Company Has Failed to Generate Any Meaningful Value from TSC Since Going Public and We Believe the Board Cannot Be Trusted to
Oversee the Company Going Forward&rdquo;. Please see page <FONT>15</FONT> of the Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition, LifeSci respectfully
refers the Staff to the disclosure on pages <FONT>9</FONT> through <FONT>14</FONT>
of the Proxy Statement, which discusses the Company&rsquo;s share price underperformance, poor capital allocation decisions, shareholder-dilutive
financings, failure to develop TSC into a marketable product that will allow either stockholders or the Company itself to generate value
from their investments, respectively, and the Company&rsquo;s lack of transparency with shareholders on the developmental progress of
TSC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">December 2, 2022</P><P STYLE="margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">LifeSci further believes that
the Board does not deserve stockholders&rsquo; trust given both its failure to hold an annual meeting at which directors were elected
for over 18 months, and then abruptly calling an annual meeting on an expedited timeframe. Accordingly, any stockholders discontent with
the Board and interested in submitting director nominees or stockholder proposals for the annual meeting initially only had 10 days to
do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-style: normal">&#183;</FONT></TD><TD STYLE="text-align: justify">&#8220;The points below are a non-comprehensive list of what appear to us to be operational missteps,
poor capital allocation decisions and other actions generally not in the best interest of stockholders:&#8221; (pg. 15).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">LifeSci acknowledges the Staff&rsquo;s
comment and has revised the Proxy Statement as follows to clearly indicate that this is a statement of opinion: &ldquo;We believe the
points below represent certain significant operational missteps, poor capital allocation decisions, and other actions generally not in
the best interest of stockholders&rdquo;. Please see page <FONT>15</FONT> of the Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">In your response letter, explain why LifeSci Capital LLC has not been included as a participant in this
solicitation. See Instructions 3(a) to Items 4 and 5 of Schedule 14A. We note the disclosure in the Background section stating that Mr.
Dobkin is a Managing Director of LifeSci Capital and it has, on behalf of unnamed clients, made an offer to acquire the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">LifeSci acknowledges the
Staff&rsquo;s comment and respectfully advises the Staff that it believes LifeSci Capital LLC (&ldquo;LifeSci Capital&rdquo;) does not
fit within the definition of &ldquo;participant&rdquo; or &ldquo;participant in a solicitation&rdquo;, as defined in Instructions 3(a)
to Items 4 and 5 of Schedule 14A. Specifically, LifeSci Capital (i) is not and will not be soliciting proxies; (ii) is not and will not
be a member of a committee or group, or acting in concert with any member of a committee or group, which solicits proxies, or directly
or indirectly takes the initiative, or engages, in organizing, directing, or arranging for the financing of any such committee or group;
(iii) is not and will not be financing or joining with another to finance the solicitation of proxies; and (iv) is not and will not be
lending money or furnishing credit nor has it entered into any other arrangements, contracts or understandings with a participant, for
the purpose of financing or otherwise inducing the purchase, sale, holding or voting of securities of the Company by any participant or
other person, in support of or in opposition to a participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">In addition, LifeSci respectfully
advises the Staff that, as disclosed on pages <FONT>8</FONT> and <FONT>16</FONT>,
the offer to acquire all outstanding shares of the Company sent by LifeSci Capital on behalf of its client was rejected by the Board.
Accordingly, neither LifeSci Capital nor any of its clients are a party to any current or pending proposal to acquire the Company.</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">December 2, 2022</P><P STYLE="margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">For these reasons, LifeSci
believes that LifeSci Capital does not need to be included as a participant in this solicitation.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify">See our last comment above. Whether or not it is a participant in this solicitation, LifeSci Capital is
an affiliate of existing participants in this solicitation, including Mr. Dobkin, who is its Managing Director. According to disclosure
in the proxy statement, it acted as an investment bank and presented an offer to acquire the Company on behalf of its client. In addition,
it appears that LifeSci Capital also sought to engage with the Company on behalf of additional clients with respect to other kinds of
strategic alternatives involving Diffusion. Therefore, please provide the information required by Item 5 of Schedule 14A regarding interests
in the Company. For example, if participants in this solicitation, by virtue of their interest in or affiliation with LifeSci Capital,
stand to gain through a transaction between clients of LifeSci and Diffusion, this interest should be described (and quantified, to the
extent possible) in the proxy statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">LifeSci acknowledges the
Staff&rsquo;s comment and has revised the Proxy Statement to disclose that Mr. Dobkin, by virtue of his relationship with LifeSci Capital,
where he serves as a managing director, will be entitled to receive certain fees and related compensation should any of LifeSci Capital&rsquo;s
investment banking clients complete a transaction with the Company. Please see page <FONT>32</FONT> of
the Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, LifeSci offers
the Staff the following information on a supplemental basis. While Mr. Dobkin is <I>a </I>managing director of LifeSci Capital, he is
one of six managing directors within LifeSci Capital&rsquo;s Investment Banking division, which is just one of three divisions at LifeSci
Capital, including the Equity Research and Equity Capital Markets divisions. Further, as discussed above in response to Comment 5, while
LifeSci Capital had previously sent a proposal to the Company on behalf of its client offering to acquire all the outstanding shares of
the Company, this offer was rejected by the Board, and there are no other offers or proposals by LifeSci Capital or any of its clients
to engage in a transaction with the Company currently outstanding. Accordingly, except as disclosed in the Proxy Statement, neither LifeSci
Capital nor any of the other participants in this solicitation has any substantial interest, by security holdings or otherwise, in any
matter to be acted upon at the annual meeting. Notwithstanding the foregoing, as discussed above, LifeSci Capital has revised the Proxy
Statement to disclose that Mr. Dobkin, by virtue of his relationship with LifeSci Capital, will be entitled to receive certain fees and
related compensation should any of LifeSci Capital&rsquo;s investment banking clients complete a transaction with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">*&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The Staff is invited to
contact the undersigned with any comments or questions it may have. We would appreciate your prompt advice as to whether the Staff has
any further comments. Thank you for your assistance.</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">December 2, 2022</P><P STYLE="margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 3.5in">Sincerely,<BR>
<BR>
/s/ Andrew Freedman<BR>
<BR>
Andrew M. Freedman</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">cc:</TD><TD STYLE="text-align: justify">David Dobkin, LifeSci Special Opportunities Master Fund Ltd.<BR>
Dorothy Sluszka, Olshan Frome Wolosky LLP<BR>
Ian Engoron, Olshan Frome Wolosky LLP</TD></TR></TABLE>

</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
